<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40404614</article-id><article-id pub-id-type="pmc">PMC12098869</article-id>
<article-id pub-id-type="publisher-id">59960</article-id><article-id pub-id-type="doi">10.1038/s41467-025-59960-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>An mRNA-display derived cyclic peptide scaffold reveals the substrate binding interactions of an N-terminal cysteine oxidase</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1824-4313</contrib-id><name><surname>Jiramongkol</surname><given-names>Yannasittha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3034-3840</contrib-id><name><surname>Patel</surname><given-names>Karishma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Johansen-Leete</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maxwell</surname><given-names>Joshua W. C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Yiqun</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7750-4413</contrib-id><name><surname>Du</surname><given-names>Jonathan J.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Passioura</surname><given-names>Toby</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0503-7166</contrib-id><name><surname>Cook</surname><given-names>Kristina M.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3618-9226</contrib-id><name><surname>Payne</surname><given-names>Richard J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1431-0339</contrib-id><name><surname>White</surname><given-names>Mark D.</given-names></name><address><email>mark.white@sydney.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>School of Chemistry, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Faculty of Science, Charles Perkins Centre, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>School of Life and Environmental Sciences, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>School of Pharmacy, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Sydney Analytical Core Research Facility, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Faculty of Medicine and Health, Charles Perkins Centre, </institution><institution>The University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>4761</elocation-id><history><date date-type="received"><day>20</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>8</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">N-terminal cysteine oxidases (NCOs) act as enzymatic oxygen (O<sub>2</sub>) sensors, coordinating cellular changes to hypoxia in animals and plants. They regulate the O<sub>2</sub>-dependent stability of proteins bearing an N-terminal cysteine residue through the N-degron pathway. Despite their important role in hypoxic adaptation, which renders them potential therapeutic and agrichemical targets, structural information on NCO substrate binding remains elusive. To overcome this challenge, we employed a unique strategy by which a cyclic peptide inhibitor of the mammalian NCO, 2-aminoethanethiol dioxygenase (ADO), was identified by mRNA display and used as a scaffold to graft substrate moieties. This allowed the determination of two substrate analogue-bound crystal structures of ADO. Key binding interactions were revealed, including bidentate coordination of the N-terminal residue at the metal cofactor. Subsequent structure guided mutagenesis identified aspartate-206 as an essential catalytic residue, playing a role in reactive oxygen intermediate orientation or stabilisation. These findings provide fundamental information on ADO substrate interactions, which can elucidate enzyme mechanism and act as a platform for chemical discovery.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">This work identified cyclic peptide inhibitors of a mammalian N-terminal cysteine oxidase, ADO, through mRNA display, one of which was used as a scaffold to graft substrate moieties, allowing key interactions to be assessed through structural and biochemical approaches.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Oxidoreductases</kwd><kwd>Peptides</kwd><kwd>X-ray crystallography</kwd><kwd>Biophysics</kwd></kwd-group><funding-group><award-group><funding-source><institution>Australian Research Council (ARC), grant reference number DE190100668. National Health and Medical Research Council (NHMRC), grant reference number 2008546. New South Wales (NSW) Health, grant reference number EMC72.</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Australian Research Council (ARC), grant reference number CE200100012.</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Molecular oxygen (O<sub>2</sub>) is a vital biological resource, delivery of which is impaired in many diseases due to inadequate blood perfusion<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. As a result, O<sub>2</sub> deprivation (hypoxia) contributes to some of the leading causes of death and disability in developed countries, including stroke, ischaemic heart disorders, and cancer<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. To help address these therapeutic challenges, the molecular mechanisms underpinning O<sub>2</sub> homoeostasis and hypoxic adaptation have been targeted to beneficially alter low O<sub>2</sub> stress responses. This strategy has been successfully implemented in the treatment of anaemia<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup> and renal cell cancer<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Here, FDA approved drugs of the hypoxia inducible factor (HIF) system, which coordinates widespread transcriptional changes to low O<sub>2</sub> in metazoans<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, have been developed. Nevertheless, additional processes that sense and respond to hypoxia have recently been identified, providing alternative approaches to combat issues associated with O<sub>2</sub> deprivation and hypoxic stress. This includes the cysteine (Cys) branch of the N-degron pathway, which controls the O<sub>2</sub>-dependent stability of proteins bearing a co- or post-translationally exposed N-terminal (Nt-) Cys in both plants and animals<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par4">The N-degron pathway is a universal and multifaceted regulatory system, which dictates the half-life of a protein based on the identity and modification state of its Nt-amino acid<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In higher eukaryotes, Nt-Cys acts as a tertiary destabilising residue, which promotes proteasomal degradation following three sequential modifications: Nt-Cys oxidation, Nt-arginylation and ubiquitination (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). The first modification, Nt-Cys oxidation, is enzymatically regulated by Nt-Cys oxidases (NCOs), which use both atoms of O<sub>2</sub> to catalyse sulfinylation of the Nt-Cys residue<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. NCOs are kinetically tailored to couple O<sub>2</sub> availability to enzyme activity and, consequently, protein levels through a high <italic>K</italic><sub>m</sub> and low affinity for O<sub>2</sub><sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Under normoxic conditions, NCOs constitutively mark their protein substrates for removal through the Cys branch of the N-degron pathway. However, during hypoxia, NCOs become inactivated, resulting in target stabilisation and cellular change.</p><p id="Par5">In animals, the Cys branch of the N-degron pathway is regulated by the NCO 2<italic>-</italic>aminoethanethiol dioxygenase (ADO), which also plays a role in cysteamine catabolism and taurine biosynthesis<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Known ADO targets are predominantly associated with cell signalling events, such as regulators of G-protein coupled signalling (RGS) 4 and 5, and the atypical cytokine interleukin 32 (IL32), suggesting that ADO complements the transcriptional output of HIF by coordinating an earlier response to hypoxia<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. RGS4 and 5 are implicated in maintaining healthy cardiovascular function while IL32 regulates pro-inflammatory cytokine networks and promotes angiogenesis<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. RGS4, RGS5 and IL32 are also associated with various cancers, where they contribute to disease proliferation, invasiveness and migration, potentially making ADO a universal drug target for these conditions<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref></sup>. ADO, itself, has been linked to immune invasion and cancer cell redox homeostasis<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par6">Biochemically, ADO is a non-haem iron-dependent thiol dioxygenase (TDO) from the cupin fold family of enzymes, consisting of a conserved double stranded &#x003b2;-helix (DSBH) core in which the active site is situated<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. The catalytic centre comprises a ferrous iron (Fe<sup>2+</sup>), which is octahedrally coordinated by a facial triad of three histidine residues, with three water molecules occupying the remaining ligation sites at rest. ADO retains low sequence and structural homology with cysteine dioxygenase (CDO), which processes free L-Cys as part of sulphur metabolism<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. CDO coordinates L-Cys in a bidentate arrangement through ligation of the amine and thiol group, leaving one coordination site available for O<sub>2</sub> to bind in an end-on orientation<sup><xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref></sup>. This promotes formation a putative iron(III) superoxo intermediate, which reacts with the thiol through radical recombination (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>)<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. Whether the reaction proceeds through initial addition of the proximal or distal oxygen atom remains to be resolved, as no intermediates have been conclusively identified, although persulfenate species have been observed <italic>in crystallo</italic><sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>.</p><p id="Par7">Interestingly, ADO has a different distribution of amino acids in its active site relative to CDO, suggesting that it uses alternative strategies to bind and modify its substrates<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. This is supported by spectroscopic studies on the metal centre, which suggest that cysteamine, the small molecule substrate of ADO, coordinates iron in a monodentate arrangement through ligation of the thiol group, leaving two sites available for O<sub>2</sub> to bind in a side-on orientation<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. However, recent experiments contradict this view, indicating that a superoxo intermediate can form in a catalytically impaired substituent of ADO and that a free Nt-thiol, Nt-amine and active site metal are vital for protein substrate binding and turnover, both of which imply bidentate coordination<sup><xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par8">No substrate bound crystal structure of ADO, or any NCO, has been obtained, owing to the rapid turnover and low affinity of native and analogue substrate sequences<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. This has limited enzyme characterisation and rational manipulation through chemical discovery. To overcome these challenges, we employed Random nonstandard Peptide Integrated Display (RaPID) technology, a variation of mRNA display that allows the incorporation of non-standard amino acids through genetic reprogramming<sup><xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>, to identify cyclic peptide inhibitors of ADO. These efforts resulted in the discovery of targeted chemical modulators of this enzyme, which exhibit competitive and uncompetitive inhibition modes based on their kinetic properties. One of the cyclic peptide inhibitors was then used as a scaffold to graft a series of substrate analogue motifs bearing a pseudo-Nt-Cys or -Ser residue, allowing two complex crystal structures of ADO to be determined at high resolution. In both structures the Nt-residue coordinates the metal centre in a bidentate arrangement, leaving one ligation site for O<sub>2</sub> to bind in an end-on orientation, analogous to CDO. Conserved active site residues were subsequently probed through mutagenesis, highlighting amino acids involved in binding and activity, with ADO-D206 identified as an essential catalytic residue. Given its position relative to the O<sub>2</sub> binding site, ADO-D206 may play a role in orientating, directing or stabilising a reactive oxygen intermediate, ensuring correct reaction with the substrate thiol. Together this work can help elucidate NCO mechanism and facilitate the rational development of new and improved ADO inhibitors to study and manipulate the Cys branch of the N-degron pathway in the context of hypoxic disease.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>The identification and characterisation of cyclic peptide inhibitors of ADO</title><p id="Par9">To provide chemical tools to selectively probe and manipulate ADO activity, RaPID was used to identify cyclic peptide (CP) inhibitors of human ADO. A semi-randomised library of DNA was transcribed into RNA, ligated to puromycin, and translated in vitro to generate a pool of over 10<sup>12</sup> CPs linked to their corresponding mRNA/cDNA &#x02018;barcodes&#x02019; (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). Peptides were initiated with <italic>N</italic>-chloroacetyl-L-tyrosine to promote spontaneous cyclisation with a downstream Cys through thioether formation. This library was incubated with biotinylated ADO, immobilised on streptavidin beads, to pull out high affinity binding partners. Bound DNA sequences were recovered, amplified by PCR, and used as the starting material for additional selection rounds.<fig id="Fig1"><label>Fig. 1</label><caption><title>The identification and characterisation of cyclic peptide (CP) inhibitors of ADO.</title><p><bold>a</bold> A schematic&#x000a0;highlighting the key steps of RaPID. Generated using Adobe Illustrator, Revvity Chemdraw and CCP4MG. Protein coordinates were obtained from the PDB using accession code 8UAN. <bold>b</bold> A sequence alignment of the top eight unique CPs discovered for ADO. <bold>c</bold> Single-dose inhibition assays: Relative enzymatic activity of ADO with RGS5<sub>2-15</sub> (100&#x02009;&#x000b5;M) in the presence of CP (10&#x02009;&#x000b5;M) at 37&#x02009;&#x000b0;C. The average of three independent experiments (<italic>n</italic>&#x02009;=&#x02009;3) is shown (error bars show the standard error). <bold>d</bold> Biophysical analysis and inhibitory responses of CP1 and CP6. (<italic>Left</italic>) Single-cycle kinetic (SCK) SPR sensorgrams of CP1 and CP6 with ADO. The sensorgrams are shown in red and the fits to the data are shown in black. The concentrations of CPs used in the titration and the equilibrium dissociation constants (<italic>K</italic><sub>D</sub>) are shown (<italic>K</italic><sub>D</sub> given as the geometric mean of a minimum of three independent SPR measurements (<italic>n</italic>&#x02009;=&#x02009;3) with standard error). (<italic>Middle</italic>) Dose-response curves with the half-maximal inhibitory concentration (IC<sub>50</sub>) values for CP1 and CP6. The average of three independent experiments (<italic>n</italic>&#x02009;=&#x02009;3) is shown (error bars show the standard error). (<italic>Right</italic>) Michaelis-Menten kinetic plots of ADO activity in the absence and presence of CP1 and CP6 performed under aerobic conditions at 37&#x02009;&#x000b0;C. The average of three independent experiments (<italic>n</italic>&#x02009;=&#x02009;3) is shown (error bars show the standard error). Source data are provided as Source Data file.</p></caption><graphic xlink:href="41467_2025_59960_Fig1_HTML" id="d33e580"/></fig></p><p id="Par10">After six cycles, clear enrichment of several CPs was observed by next-generation sequencing. The most enriched CPs (CP1-8, numbered according to their percentage enrichment in the final selection round) were selected for subsequent analysis (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). CP1, 5, 6 and 7 are related in sequence, while CP2, 3, 4, and 8 are unique compositions (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). These CPs were subsequently produced by solid-phase peptide synthesis (SPPS) and analysed by surface plasmon resonance (SPR) using single cycle kinetic (SCK) analysis to confirm and quantify binding to ADO. ADO could interact with each CP to varying degrees (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref><italic>left</italic>). CP1, 5, 6, and 8 exhibited the tightest interactions, generating equilibrium dissociation constants (<italic>K</italic><sub>D</sub>) of 35, 40, 66, and 5&#x02009;nM, respectively, while CP2, 3, and 4 displayed significantly lower binding affinities, with <italic>K</italic><sub>D</sub> values of &#x0003e;5000, &#x0003e;5000, and 1300&#x02009;nM. Unfortunately, CP7 was not amenable to affinity quantification by SPR as it displayed non-specific binding at the concentrations tested, which resulted in a significantly slow off rate (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>A summary of the cyclic peptides identified by RaPID and their biophysical and inhibitory properties</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CP</th><th>Sequence</th><th>Enrichment (%)</th><th><italic>K</italic><sub>D</sub> (nM)</th><th>IC50 (&#x000b5;M)</th><th>Inhibition mode (apparent)</th></tr></thead><tbody><tr><td>1</td><td>YTVSTTWLGTHRQC</td><td>9.0</td><td>35&#x02009;&#x000b1;&#x02009;2.1</td><td>1.72&#x02009;&#x000b1;&#x02009;0.23</td><td>Competitive</td></tr><tr><td>2</td><td>YRIIRVFRSWVLCPC</td><td>4.3</td><td>&#x0003e;5000</td><td>&#x0003e;50</td><td>-</td></tr><tr><td>3</td><td>YWTLNEGFPRRGRLC</td><td>2.6</td><td>&#x0003e;5000</td><td>-</td><td>-</td></tr><tr><td>4</td><td>YYYVLGTILVKRYRFC</td><td>2.0</td><td>1300&#x02009;&#x000b1;&#x02009;140</td><td>&#x0003e;50</td><td>-</td></tr><tr><td>5</td><td>YITITSWLGTLRQC</td><td>1.8</td><td>40&#x02009;&#x000b1;&#x02009;0.80</td><td>5.68&#x02009;&#x000b1;&#x02009;0.53</td><td>Competitive</td></tr><tr><td>6</td><td>YIVKTFWLGSHRQC</td><td>1.7</td><td>66&#x02009;&#x000b1;&#x02009;0.86</td><td>0.95&#x02009;&#x000b1;&#x02009;0.05</td><td>Uncompetitive</td></tr><tr><td>7</td><td>YLLVTLYLGTHRSC</td><td>1.5</td><td>-</td><td>9.92&#x02009;&#x000b1;&#x02009;0.29</td><td>-</td></tr><tr><td>8</td><td>YTYRYPSILRVWARYGC</td><td>1.1</td><td>4.7&#x02009;&#x000b1;&#x02009;0.35</td><td>1.73&#x02009;&#x000b1;&#x02009;0.02</td><td>Uncompetitive</td></tr></tbody></table><table-wrap-foot><p>Values were calculated using data presented in Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>, <xref rid="MOESM1" ref-type="media">5</xref> and <xref rid="MOESM1" ref-type="media">7</xref>. Cyclisation occurs between <italic>N</italic>-chloroacetyl-L-tyrosine, in position one, and the first cysteine in the sequence.</p></table-wrap-foot></table-wrap></p><p id="Par11">We next tested the ability of the CPs to inhibit ADO activity. ADO activity was measured with and without 10 &#x003bc;M of each CP using an established stopped assay in which the oxidation of a representative substrate (RGS5<sub>2-15</sub>; a synthetic peptide corresponding to the methionine excised N-terminus of RGS5, residues 2 to 15) was monitored by liquid chromatography coupled mass spectrometry (LCMS)<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Every CP except CP3, which demonstrated the weakest <italic>K</italic><sub>D</sub> by SPR, reduced ADO activity, with CP1, 5, 6, and 8 displaying the greatest impact on substrate turnover (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>). Inhibition was subsequently quantified through half-maximal inhibitory concentration (IC<sub>50</sub>) measurements, confirming that CP1, 5, 6, and 8 are the most potent inhibitors, with IC<sub>50</sub> values in the single digit &#x003bc;M range (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5</xref>, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref><italic>middle</italic>).</p><p id="Par12">The inhibition modes of CP1, 5, 6, and 8 were initially assessed using a SPR-based competition assay, which monitored the binding of full-length RSG5 (RGS5<sup>FL</sup>; which is ~10 times larger than the CPs) to ADO in the presence of different concentrations of CP. Each inhibitor could impede RGS5 association, as demonstrated by a decrease in response signal, suggesting that CP1, 5, 6, and 8 preferentially bind at the ADO active site compared to native substrate (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6</xref>). The modes of inhibition were further characterised using the Michaelis Menten model of enzyme kinetics, by comparing the kinetic parameters of ADO with and without CP1, 5, 6, and 8. Each CP was added at its IC<sub>50</sub> concentration to capture changes in substrate association and turnover during partial inactivation of the enzyme (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref><italic>right</italic>). This revealed that CP1 and 5 are competitive inhibitors, which increase the apparent <italic>K</italic><sub>m</sub> of ADO, without altering <italic>k</italic><sub>cat</sub>, while CP6 and 8 exhibit the kinetic properties of uncompetitive inhibitors, decreasing both the apparent <italic>K</italic><sub>m</sub> and <italic>k</italic><sub>cat</sub>. This was unexpected as CP1, 5, and 6 are related in sequence (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). However, CP6 contains two unique residues, K4 and F6, which may influence inhibitor behaviour.</p><p id="Par13">Together this established targeted inhibitors of ADO, which exhibited distinct modes of action as demonstrated by changes in apparent substrate association and enzyme turnover.</p></sec><sec id="Sec4"><title>CP6 inhibits ADO by blocking the active site and detracting a putative catalytic residue</title><p id="Par14">A crystal structure of ADO in complex with CP6 was obtained through co-crystallisation to characterise its binding mode and evaluate how differences in CP sequence can influence the means of inhibition. Initial attempts to crystallise CP6 in complex with wild-type ADO proved unsuccessful. However, two crystal structures of unbound ADO, which were published during this investigation, highlighted alterations that result in an amenable crystallisation construct, including metal cofactor substitution and surface Cys mutations<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. Following these strategies, a crystal structure of cobalt-incorporated ADO in complex with CP6 was obtained at 1.74&#x02009;&#x000c5; resolution (Protein Data Bank [PDB] ID: 9DXU; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>, Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>&#x02013;<xref rid="MOESM1" ref-type="media">10</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>A crystal structure of ADO in complex with CP6 elucidates its mode of inhibition and highlights a putative catalytic residue.</title><p><bold>a</bold> The crystal structure of cobalt-incorporated ADO in complex with CP6 (1.74&#x02009;&#x000c5; resolution), displayed through ribbon, surface (transparent) and cylinder representations. CP6 (cyan) forms an antiparallel &#x003b2;-sheet, which lies across the DSBH of ADO (pink), blocking the active site. The conformation of CP6 is maintained through a series of intramolecular hydrogen bonding interactions (boxed insert). <bold>b</bold> The superimposed crystal structures of CP6-bound (light pink) and CP-free (orange; PDB: 8UAN) cobalt-incorporated ADO. CP6-F6 promotes a hydrogen bond network through ADO-E92, which pulls the sidechain of ADO-D206 away from the metal centre (boxed insert). <bold>c</bold> Michaelis-Menten kinetic plots of ADO in the absence and presence of CP6, CP6-K4A and CP6-F6S under aerobic conditions at 37&#x02009;&#x000b0;C, which highlights the role of CP6-F6 in reducing ADO turnover. Each CP was added at its half-maximal inhibitory concentration (IC<sub>50</sub>) to capture changes in substrate association and turnover during partial inactivation of the enzyme (CP6&#x02009;=&#x02009;1.0 &#x003bc;M, CP6-K4A&#x02009;=&#x02009;21 &#x003bc;M and CP6-F6S&#x02009;=&#x02009;0.2 &#x003bc;M) The average of three independent experiments (<italic>n</italic>&#x02009;=&#x02009;3) is shown (error bars show the standard error). Source data are provided as Source Data file.</p></caption><graphic xlink:href="41467_2025_59960_Fig2_HTML" id="d33e887"/></fig></p><p id="Par15">CP6 adopts an antiparallel &#x003b2;-sheet conformation, which is maintained through a series of intramolecular hydrogen bonds between backbone and sidechain atoms (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>). The peptide sits across one end of the DSBH core of ADO, blocking the active site entrance. CP6 binding is mediated by a number of intermolecular interactions, including pi-stacking between the sidechain of CP6-W7 and the sidechain of ADO-Y87, pi-stacking between the C-terminal amide of CP6-C14 and the sidechain of ADO-W257, and hydrogen bonds between the sidechain of CP6-R12 and the backbone carbonyls of ADO-Q252, -A253 and -F256 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>).</p><p id="Par16">Globally, CP6 binding causes minor changes in ADO structure, with superimposition based on secondary structure matching resulting in a root mean squared deviation (RMSD) of 0.74 when compared to PDB:8UAN, a crystal structure of cobalt-incorporated ADO in the absence of a CP (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>, Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>; 220 residues aligned)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. However, specific permutations are observed, including a shift in a hairpin loop (residues 212 to 220), which moves ~2&#x02009;&#x000c5; away from CP6 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>). Additional changes in ADO structure are largely restricted to amino acid sidechains including, most notably, ADO-W257, which rotates to stack with the C-terminal amide of CP6-C14, and ADO-E92, which adopts a distinct conformation to avoid clashing with CP6-F6 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). Additional electron density is observed around the active site metal, which was modelled as Tris coordinating cobalt in multiple conformations (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10</xref>). Tris is known to interact with metal ions and has been observed coordinating with the metal centre of plant cysteine oxidase 2 (PCO2), a structural and functional homologue of ADO<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Nevertheless, given the complexity of the density, other interpretations are possible.</p><p id="Par17">As stated above, CP6 contains two unique residues, K4 and F6, which are the most likely candidates for reducing ADO turnover and conferring the kinetic characteristics of an uncompetitive inhibitor based on sequence alignments with CP1 and 5, which act as competitive inhibitors. CP6-K4 and -F6 interact with ADO-D215 and ADO-E92, respectively. While there is no immediate rationale for the functional contribution of the former, CP6-F6 promotes formation of a hydrogen bonding network down to the active site via ADO-E92, -H89, -Y87 and a water molecule, which is not present in the peptide-free structure. This pulls the side chain of ADO-D206, a putative catalytic residue, away from the metal centre (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p><p id="Par18">To confirm the importance of these interactions in reducing ADO turnover, two single amino acid substituents of CP6, CP6-K4A and -F6S, were synthesised and assessed (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). While CP6-K4A had a large impact on CP and substrate association, increasing the <italic>K</italic><sub>D</sub>, IC<sub>50</sub> and apparent <italic>K</italic><sub>m</sub> (relative to CP6), CP6-F6S had a significant effect on turnover, increasing the apparent <italic>k</italic><sub>cat</sub> (relative to CP6) from 16&#x02009;s<sup>-1</sup> to 38&#x02009;s<sup>-1</sup> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>). A similar trend was observed when CP was added at two times the IC<sub>50</sub> concentration (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">12</xref>, Supplementart Table&#x000a0;<xref rid="MOESM1" ref-type="media">5</xref>). The role of ADO-E92 was also assessed through mutagenesis. In the presence of ADO-E92A, CP6 exhibited characteristics that more closely align with a competitive inhibitor, increasing the apparent <italic>K</italic><sub>m</sub> and <italic>k</italic><sub>cat</sub> relative to the DMSO control and wild-type ADO in the presence of CP6, respectively (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">13</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">6</xref>).</p><p id="Par19">Together, this suggests that CP6-F6 reduces turnover and instils the kinetic properties of an uncompetitive inhibitor by promoting the formation of an ADO-E92-mediated hydrogen bonding network down to the active site that pulls ADO-D206 into an unfavourable conformation. Accordingly, CP6 appears to inhibit ADO by both blocking the active site and detracting a putative catalytic residue.</p></sec><sec id="Sec5"><title>Employing CP6 as a scaffold to graft substrate moieties and determine ADO binding interactions</title><p id="Par20">Structural information on ADO substrate binding has been elusive. Several attempts to crystallise ADO in complex with different substrate constructs and analogues proved unsuccessful due to product formation and low affinity, respectively, even following active site metal substitution. To overcome these issues, CP6 was used as a molecular scaffold to graft substrate moieties, anticipating that its binding and inhibition properties would enhance substrate complex formation by increasing association and reducing turnover.</p><p id="Par21">CP6-L8 protrudes into the active site of ADO without contributing to binding, rendering it a viable site for substrate moiety installation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a, b</xref>, Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">14</xref>). In the first instance, CP6-L8 was replaced with ornithine (Orn; O) or lysine (Lys), allowing the sidechain amine to be coupled to Cys or serine (Ser), the latter of which is an amenable substrate analogue<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. This generated a pseudo-N-terminus with conformational and rotational flexibility, which could reach the ADO active site metal (a distance of 7.5&#x02009;&#x000c5;; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">14</xref>). The association of these CP6-substituents was assessed by SPR using SCK, revealing that Cys and Ser conjugated to a Lys sidechain enhanced binding relative to unmodified CP6 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">15</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). Encouraged by this data, co-crystallisation trials with CP6-L8K coupled to Cys and Ser were conducted, resulting in a crystal structure of cobalt-incorporated ADO in complex with CP6-L8K-Ser at 1.60&#x02009;&#x000c5; resolution (PDB:9DXV; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>). The Ser residue of CP6-L8K-Ser coordinates the metal centre in a bidentate arrangement through ligation of both the hydroxyl and amine group, leaving one water molecule trans to ADO-H112, which is the putative site of oxygen binding and activation. The water molecule trans to ADO-H112 also forms a hydrogen bond with ADO-D206, which points towards the metal centre through an additional interaction with the amine of CP6-L8K-Ser. This causes ADO-D206 to adopt the same orientation as the peptide-free cobalt-incorporated structure (PDB:8UAN)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, suggesting that substrate (analogue) binding disassembles the hydrogen bonding network promoted by ADO-E92 in the presence of CP6-F6 by enhancing an interaction with the metal centre. Nt-Ser binding is further supported by three protein-mediated interactions: a hydrogen bond between the hydroxyl group of Nt-Ser and the hydroxyl group of Y212, a hydrogen bond between the amine group of Nt-Ser and the carboxylic acid/carboxylate group of D206, and pi-stacking between the amide of Nt-Ser and the sidechain of F101 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Employing CP6 as a scaffold to graft substrate moieties.</title><p><bold>a</bold> The crystal structure of cobalt-incorporated ADO (pink) in complex with CP6 (cyan), displayed as cylinders, highlighting the position and distance of CP6-L8 relative to the metal centre of ADO. <bold>b</bold> The chemical structure of CP6, highlighting the position of CP6-L8, the site of substrate moiety installation. <bold>c</bold> Biophysical analysis of CP6 substituents bearing a substrate moiety. (<italic>Left</italic>) Representative chemical structures of the substrate moieties grafted onto CP6 (represented as a circle) through substitutions in CP6-L8. &#x02018;O&#x02019; corresponds to ornithine and &#x02018;d&#x02019; corresponds to 2,3-diaminopropionic acid. (<italic>Right</italic>) SCK SPR sensorgrams of CP6 substituents bearing a substrate moiety with ADO. The sensorgrams are shown in red and the fits to the data are shown in black. The concentrations of CPs used in the titration and equilibrium dissociation constants (<italic>K</italic><sub>D</sub>) are shown (<italic>K</italic><sub>D</sub> given as the geometric mean of a minimum of three independent SPR measurements (<italic>n</italic>&#x02009;=&#x02009;3)). Source data are provided as Source Data file.</p></caption><graphic xlink:href="41467_2025_59960_Fig3_HTML" id="d33e1079"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><title>A crystal structure of ADO in complex with CP6-L8K-Ser reveals key substrate binding interactions.</title><p>The crystal structure of cobalt-incorporated ADO (dark pink) in complex with CP6-L8K-Ser (light blue; 1.60&#x02009;&#x000c5; resolution), displayed through ribbon, surface and cylinder representations, with 2Fo-Fc electron density shown as a blue mesh contoured to 1 sigma. The pseudo-Nt-Ser residue coordinates the metal cofactor in a bidentate arrangement through ligation of the hydroxyl and amine groups (boxed insert). ADO-F101 forms a pi-stacking interaction with the substrate amide, while ADO-Y212 and -D206 form hydrogen bonds with the hydroxyl and amine groups of Nt-Ser, respectively. ADO-D206 also interacts with the water molecule trans to ADO-H112, which is the putative O<sub>2</sub> binding site.</p></caption><graphic xlink:href="41467_2025_59960_Fig4_HTML" id="d33e1090"/></fig></p><p id="Par22">Following successful implementation of this strategy in generating a structure of ADO in complex with a substrate analogue, additional moieties were installed onto CP6 to examine interactions with extended pseudo-N-terminal sequences. CP6-L8 was replaced with 2,3-diaminopropionic acid (Dap; d), an amino acid that contains a sidechain amine linked to one carbon, from which the dipeptides Lys-Ser, Phe-Ser, and Gly-Ser were appended, to mimic the N-termini of known NCO substrates (RGS4/5, IL32, and RAP2 [an NCO target in plants<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>], respectively; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). Although each substituent reduced binding affinity relative to CP6, with CP6-L8d-Lys-Ser, CP6-L8d-Phe-Ser, and CP6-L8d-Gly-Ser generating <italic>K</italic><sub>D</sub> values of 490, 79, and 150&#x02009;nM, respectively, a crystal structure of cobalt-incorporated ADO in complex with CP6-L8d-Gly-Ser was obtained at 1.74&#x02009;&#x000c5; resolution (PDB:9DXB; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">16</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>). The pseudo-Nt-Ser residue remains coordinated to the metal centre in a bidentate arrangement, supported by interactions with ADO-F101, -D206 and -Y212, with one water molecule trans to ADO-H112, analogous to CP6-L8K-Ser. No additional interactions are observed except, possibly, weak water-mediated hydrogen bonds between the second amide of CP6-L8d-Gly-Ser and the sidechain hydroxyls of ADO-Y212 and -Y222, as these water molecules are absent in the CP6-L8K-Ser structure.</p><p id="Par23">Together these crystal structures provide molecular descriptions of an ADO substrate complex, highlighting key binding interactions (including bidentate coordination of the Nt-residue), which can inform both reaction mechanism and rational inhibitor design.</p></sec><sec id="Sec6"><title>Verifying active site interactions and residues</title><p id="Par24">The crystal structures of cobalt-incorporated ADO in complex with CP6-L8K-Ser and CP6-L8d-Gly-Ser provide valuable information on substrate analogue binding. However, they do not reflect native conditions in which an iron cofactor interacts with an Nt-Cys residue. To corroborate that the crystal structures of cobalt-incorporated ADO in complex with CP6-L8K-Ser and CP6-L8d-Gly-Ser are biologically relevant, molecular dynamic (MD) simulations were conducted with different combinations of active site metal and pseudo-N-terminal substrate residues over 100&#x02009;ns (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">18</xref>). In each instance, no changes in hydrogen bonding distance were observed, with Ser and Cys interacting with cobalt(II) and iron(II) through ligation of both their amine and hydroxyl/thiol groups, supporting bidentate coordination of the substrate. The water molecule trans to ADO-H112 remains within hydrogen bonding distance of the metal, with minimal changes in ADO structure, as determined by RMSD (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">19a</xref>). MD was also used to calculate the binding energies associated with CP6-L8d-Gly-Ser/Cys complex formation, verifying key residue interactions, most notably the contributions of ADO-Y87 and CP6-W7, ADO-W257 and CP6-C14, ADO-Y212 and CP6-L8d-Gly-Ser/Cys, all of which were highlighted above during assessment of the crystal structure (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">19</xref>). It also emphasised the role of ADO-Q252, which forms hydrogen bonds with the backbone nitrogen and oxygen of CP6-R12 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>).</p><p id="Par25">Having verified the accuracy of the substrate analogue-bound crystal structures using MD simulations, key active site residues were mutated to assess their impact on binding and activity using SPR and LCMS. They were chosen based on their proximity to the substrate moieties and their conservation across species, including plants, where NCOs are called plant cysteine oxidases (PCOs; Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>)<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. Two representative substrates, RGS5<sub>2-15</sub> and IL32<sub>2-15</sub> (a synthetic peptide corresponding to the methionine excised N-terminus of IL32, residues 2&#x02013;15), were tested to compare interactions with different amino acid sequences.<fig id="Fig5"><label>Fig. 5</label><caption><title>The identification of ADO residues involved in substrate binding and turnover.</title><p><bold>a</bold> A sequence alignment comparing the amino acid composition of different NCOs, including ADOs (human, mouse and fruit fly) and PCOs (arabidopsis, rice and wheat). Red background and white text highlights conserved residues. M denotes residues involved in metal cofactor coordination. An asterisk (*) denotes residues mutated during this study. A black asterisk denotes residues mutated for substrate binding and activity measurements. A red asterisk (*) denotes ADO-E92, which was mutated for CP6 characterisation. <bold>b</bold> The active site of cobalt-incorporated ADO (dark pink) in complex with CP-L8K-Ser (light blue), highlighting the residues mutated in this study (opaque). <bold>c</bold> Biophysical and activity analysis of ADO mutants with RGS5<sub>2-15</sub> (black) or IL32<sub>2-15</sub> (grey). (<italic>Top panel</italic>) The fold difference in equilibrium dissociation constant (<italic>K</italic><sub>D</sub>) relative to wild type ADO (<italic>K</italic><sub>D</sub> calculated as the geometric mean of a minimum of three independent SPR measurements (<italic>n</italic>&#x02009;=&#x02009;3); error bars show the standard error). D206A (bold italics) displayed no binding. (<italic>Bottom</italic>) The specific activity relative to wild type ADO. Conducted at 37&#x02009;&#x000b0;C under aerobic conditions using 1&#x02009;mM substrate. The average of three independent experiments (<italic>n</italic>&#x02009;=&#x02009;3) is shown (error bars show the standard error). Source data are provided as Source Data file.</p></caption><graphic xlink:href="41467_2025_59960_Fig5_HTML" id="d33e1188"/></fig></p><p id="Par26">From a binding perspective, changes in ADO-F101 and -Y212 caused the largest deviation in dissociation for both substrates, increasing <italic>K</italic><sub>D</sub> up to 80 and 113-fold, respectively (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref><italic>upper panel</italic>, Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">20</xref> and <xref rid="MOESM1" ref-type="media">21</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">7</xref>). This correlates with observations from the crystal structure that they support Nt-residuebinding through pi-stacking and hydrogen bonding interactions. No binding was observed for ADO-D206A, while ADO-D206N moderately increased affinity 4 to 7-fold. ADO-I109A was the only variant to exhibit a substrate specific change, increasing the <italic>K</italic><sub>D</sub> of RGS5<sub>2-15</sub> and IL32<sub>2-15</sub> 2 and 35-fold, respectively, suggesting it participates in a specific interaction with the latter, possibly residue IL32<sub>2-15</sub>-F3, which is important for binding<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par27">Specific activity was measured under saturating substrate concentrations (1&#x02009;mM) to identify residues involved in catalysis (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref><italic>bottom panel</italic>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>). While fluctuations in activity were observed, which might reflect changes in substrate binding affinity, particularly for ADO-F101 which exhibited reduced activity with both substrates, mutants of D206 significantly impacted turnover. ADO-D206A and -D206N reduced activity by 99 and 98%, respectively (the latter of which can be attributed to impaired substrate binding), while D206E reduced activity by 80%. This indicates that ADO-D206 is an essential catalytic residue, which facilitates turnover through its carboxylic acid/carboxylate group, as ADO-D206E retains some activity, suggesting ADO-D206 contributes to turnover through acid/base chemistry or its charge properties.</p><p id="Par28">ADO cannot bind oxidised peptide or protein sequences&#x000a0;(i.e. those bearing Nt-Cys sulfinic acid/sulfinate)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. To explore whether ADO-D206 plays a role in product release through protonation or charge repulsion, the binding of oxidised RGS5<sub>2-15</sub> and IL32<sub>2-15</sub> to ADO-D206N was monitored by SPR (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">22</xref>). No association was observed up to 100 &#x003bc;M, suggesting that ADO-D206 does not promote Nt-Cys sulfinic acid/sulfinate release. Given its position in the active site (and the fact that many ADO-D206 variants bind substrate), this implies that ADO-D206 contributes to ADO activity through an interaction with O<sub>2</sub> during turnover.</p></sec></sec><sec id="Sec7" sec-type="discussion"><title>Discussion</title><p id="Par29">ADO has emerged as a potential therapeutic target due to its role in O<sub>2</sub> sensing and hypoxic adaptation. However, there is no structural information on substrate binding, impeding molecular discovery and enzyme characterisation. To address these issues, we employed a unique strategy by which substrate moieties were grafted onto an mRNA-display derived cyclic peptide scaffold. This allowed the crystal structures of an ADO complex to be determined, which highlights key substrate binding interactions and potential reaction mechanisms. In both structures, the substrate analogue coordinates the metal cofactor in a bidentate arrangement through ligation of both the hydroxyl and amine group, leaving one ligation site available for O<sub>2</sub> to bind in an end on orientation, analogous to the homologue CDO<sup><xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref></sup>. This suggests that oxygen activation proceeds through an iron(III) superoxo intermediate, which reacts with the thiol via radical recombination as proposed for other TDOs<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. Whether this occurs through addition of the proximal oxygen in a concerted mechanism, resulting in the formation of a persulfenate intermediate, or through addition of the distal oxygen in a step wise mechanism, which produces an iron(IV) oxo species, remains to be resolved (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">23</xref>). However, a recent spectroscopic paper provides evidence for the former, as no high valent (i.e. iron(IV) oxo) intermediate was detected in a catalytically impaired ADO complex, which turns over slowly<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>.</p><p id="Par30">Despite multiple attempts, we were unable to generate crystals of ADO in complex with CP6-L8K-Cys. This may be the result of thiol oxidisation and/or peptide dimerisation as ADO does not bind sulfinic acid/sulfinate and Nt-Cys readily forms disulphide bonds<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Nevertheless, MD simulations suggest that the binding mode observed in our crystal structures reflects the native interaction as no change in hydrogen bonding distance is observed when ferrous iron (Fe<sup>2+</sup>) and Nt-Cys (the native constituents) are added to the model, with both amine and thiol groups remaining in contact with the metal over a 100&#x02009;ns simulation. Furthermore, previous biophysical experiments have demonstrated that a free N-terminal thiol, a free N-terminal amine, and an active site metal (Fe<sup>2+</sup>, Zn<sup>2+</sup> or Co<sup>2+</sup>) are vital for ADO substrate engagement, supporting bidentate coordination<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. This work also demonstrated that Nt-Ser can substitute Nt-Cys in terms of binding, albeit at the cost of affinity, rendering it an amenable analogue for structural studies. Some spectroscopic experiments have proposed that the substrate thiol ligates the iron cofactor in a monodentate arrangement, leaving two coordination sites for O<sub>2</sub> to bind in a side-on orientation<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. However, most of these studies used cysteamine instead of an amino acid sequence bearing an Nt-Cys. This renders our structural information more reliable in regard to initial protein substrate complex formation. Nevertheless, we cannot rule out that changes in metal coordination occur during turnover, as observed for other non-haem iron-dependent enzymes<sup><xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p><p id="Par31">NCOs have low sequence and structural homology with CDO, which processes free L-Cys as part of sulphur metabolism. However, ADO has a distinct distribution of amino acids in its active site (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">24</xref>)<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. While mutagenesis revealed that many of these differences facilitate the binding of specific substrate, such as ADO-F101, which forms a pi-stacking interaction with the substrate amide, ADO-D206 was identified as a unique catalytic residue. Activity assays with various ADO-D206 mutants revealed that the carboxylate/carboxylic acid group is important for turnover. However, biophysical measurements indicated that it does not contribute to substrate binding (by deprotonating the Nt-thiol or -amine) or product release. Instead, ADO-D206, which sits within hydrogen bonding distance of the putative O<sub>2</sub> coordination site, may orientate and/or stabilise a reactive oxygen intermediate, ensuring correct reaction with the substrate thiol. A similar role has been proposed for residue Y157 in CDO (rat numbering)<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. Given its position in the active site (it sits above the Nt-residue of the substrate, facing the same direction as the Nt-hydroxyl and Nt-amine; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), ADO-D206 may orientate the distal oxygen of the putative iron(III) superoxo species away from the thiol group through charge repulsion or orbital overlap, promoting initial reaction with the proximal oxygen (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">25a</xref>). Alternatively, ADO-D206 may direct the putative iron(III) superoxo species by transiently protonating the distal oxygen, increasing the electronegativity and reactivity of the proximal oxygen (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">25b</xref>), stabilise the reaction by preventing protonation of a reactive oxygen intermediate (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">26a</xref>), or maintain the protonation state of the water molecule occupying the O<sub>2</sub> binding site (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">26b</xref>). The latter would reduce hydroxide formation, facilitating exchange with O<sub>2</sub>. A similar role has been proposed for Y159 in the TDO 3-mercaptopropionate dioxygenase<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Another difference between ADO and CDO is substrate orientation. The substrate amine and (would be) thiol groups occupy opposite coordination sites on the metal cofactor (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">24</xref>)<sup><xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref></sup>. Unlike other eukaryotes, mammals only encode one NCO<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. While not observed in our crystal structures, it is possible that ADO binds its substrates in both orientations to increase promiscuity. This would allow the enzyme to regulate the stability of different proteins, consisting of different amino acid sequences, through the N-degron pathway, as suggested by activity assays<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. This may explain variations in binding interactions observed during this investigation (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>, and&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>). However, additional mutagenesis, substrate binding and structural analysis is required to verify this claim.</p><p id="Par32">This work also established selective modulators of ADO, a potential target for hypoxic disease. The CPs were shown to inhibit ADO through different mechanisms. CP6 impacted substrate turnover, as well as binding, through an indirect interaction with D206, emphasising the role of this residue in catalysis. While it is unlikely that the CP inhibitors described in this report will be of immediate pharmaceutical value, they do highlight important interactions which, in conjunction with the substrate analogue structures, can be used to rationally design more drug-like inhibitors. Many of the residues examined in this report are conserved in other NCOs, including the PCOs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5A</xref>), which regulate the stability of transcription factors linked to crop flood resistance<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref></sup>. As a result, these structures can also inform the design and optimisation of inhibitors with agrichemical applications. Accordingly, in addition to elucidating enzyme mechanism, this work will facilitate the development of new chemical candidates to study and manipulate the Cys branch of the N-degron pathway and associated low O<sub>2</sub> processes, which, in turn, may lead to new strategies to address hypoxic disease and improve crop stress tolerance.</p></sec><sec id="Sec8"><title>Methods</title><sec id="Sec9"><title>Protein production</title><p id="Par33">Full-length human ADO (Uniprot ID: Q96SZ5) was cloned into the pET28a (thrombin cleavage site following tag) and pETDuet (TEV cleavage site following tag) plasmids for bacterial expression as <italic>N</italic>-terminal His-tagged proteins and into the pQE80L-Navi plasmid for bacterial expression as an <italic>N</italic>-terminally His-tagged and biotinylated protein. The pET28a-ADO construct was used to produce protein for enzyme kinetic assays, the pETDuet-ADO construct was used to produce protein for X-ray crystallography, and the pQE80L-Navi-ADO construct was used to produce protein for SPR experiments. Full-length human RGS5 (Uniprot ID: O15539) was cloned into pETDuet with an <italic>N</italic>-terminal His- and SUMO-tag for bacterial expression. The pETDuet-His-SUMO-RGS5 construct was used to produce all RGS5 proteins used in this study. Site-directed mutagenesis was used to introduce mutations in the constructs listed above.</p><p id="Par34">All constructs were transformed into Rosetta2(DE3) <italic>Escherichia coli</italic> (<italic>E. coli</italic>) cells in preparation for protein expression. 2xYT, supplemented with the appropriate antibiotics, was used as the expression medium to express standard proteins. Expression cultures were inoculated with saturated overnight cultures (1:100 dilution) prepared using single colonies from fresh transformations or glycerol stocks. Expression cultures were incubated at 37&#x02009;&#x000b0;C, with shaking at 120&#x02013;150&#x02009;rpm, and allowed to grow to an OD600 of &#x0223c;0.6&#x02013;0.8 before being cooled to room temperature and supplemented with 0.5&#x02009;mM IPTG (and 0.2&#x02009;mM biotin for the pQE80L-Navi construct to enable biotinylation) to induce expression. Expression cultures were further incubated at 20&#x02009;&#x000b0;C, with shaking, for &#x0223c;18&#x02013;24&#x02009;h before harvesting via centrifugation at 4000&#x02009;<italic>g</italic> for 25&#x02009;minutes. Cell pellets were stored at &#x02013;20&#x02009;&#x000b0;C until required for protein purification.</p><p id="Par35">Cobalt-incorporated proteins were produced as described above for standard proteins up until OD600 of &#x0223c;0.6&#x02013;0.8 was reached. At this point, cultures were harvested (15&#x02009;minutes at 4000&#x02009;<italic>g</italic>) and cell pellets were resuspended in M9 minimal media supplemented with 0.2&#x02009;mM CoCl<sub>2</sub>. A volume of minimal media half the volume of the original 2xYT expression culture was used for resuspension and the appropriate antibiotics were added. The cultures were then transferred to 20&#x02009;&#x000b0;C, with shaking, for 45&#x02009;minutes before expression was induced with 0.5&#x02009;mM IPTG and allowed to proceed as described above.</p></sec><sec id="Sec10"><title>Protein purification</title><sec id="Sec11"><title>ADO prepared for RaPID screening and SPR experiments (pQE80L-NAvi-ADO)</title><p id="Par36">A purification procedure of nickel-ion (Ni<sup>2+</sup>) affinity chromatography followed by size exclusion chromatography was used to prepare the ADO used for SPR in this study. Cell pellets were resuspended in lysis buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, 20&#x02009;mM imidazole, 10&#x02009;&#x003bc;g/ml DNAse I, 100&#x02009;&#x003bc;g/ml lysozyme, and 1x cOmplete EDTA-free protease inhibitor) and lysed by sonication before being clarified via centrifugation (17,000&#x02009;g for 30&#x02009;minutes followed by filtration through a 0.45&#x02009;&#x003bc;M membrane). The soluble fractions of cell lysates were subject to Ni<sup>2+</sup>-affinity chromatography by incubating the supernatant with Ni-NTA agarose (Cytiva) equilibrated in wash buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, and 20&#x02009;mM imidazole). Bound proteins were washed and eluted with elution buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, and 500&#x02009;mM imidazole). Protein-containing fractions were concentrated and injected onto an equilibrated 26/600 HiLoad Superdex 75 prep grade column (Cytiva) and eluted using SEC buffer (20&#x02009;mM HEPES pH 7.5, 150&#x02009;mM NaCl, and 1&#x02009;mM TCEP). Protein purity was assessed by SDS-PAGE and concentrations were determined using A280 nm measurements.</p></sec><sec id="Sec12"><title>ADO prepared for enzyme assays (pET28a-ADO)</title><p id="Par37">A purification procedure of nickel-ion (Ni<sup>2+</sup>) affinity chromatography followed by size exclusion chromatography was used to prepare the ADO used for enzyme assays in this study. Cell pellets were resuspended in lysis buffer (50&#x02009;mM Tris pH 7.5, 400&#x02009;mM NaCl, 20&#x02009;mM imidazole, 10&#x02009;&#x003bc;g/ml DNAse I, and 1x cOmplete EDTA-free protease inhibitor) and lysed by sonication before being clarified via centrifugation (17,000&#x02009;g for 30&#x02009;minutes followed by filtration through a 0.45&#x02009;&#x003bc;M membrane). The soluble fractions of cell lysates were subject to Ni<sup>2+</sup>-affinity chromatography by passing the supernatant through a HisTrap HP column (Cytiva) equilibrated in wash buffer (50&#x02009;mM Tris pH 7.5, 400&#x02009;mM NaCl, 20&#x02009;mM imidazole). Bound proteins were washed and eluted using a 20&#x02009;mM to 1&#x02009;M imidazole gradient in a base buffer comprised of 50&#x02009;mM Tris pH 7.5 and 400&#x02009;mM NaCl. Protein-containing fractions were concentrated and buffer exchanged into SEC buffer (50&#x02009;mM Tris pH 7.5 and 400&#x02009;mM NaCl) using a PD-10 desalting column (Cytiva). The desalted protein was injected onto an&#x000a0;equilibrated 26/600 HiLoad Superdex 75 prep grade column (Cytiva) and eluted using SEC buffer. Protein purity was assessed by SDS-PAGE and concentrations were determined using A280 nm measurements.</p></sec><sec id="Sec13"><title>ADO prepared for X-ray crystallography (pETDuet-TEV-ADO)</title><p id="Par38">A purification procedure of cobalt-ion (Co<sup>2+</sup>) affinity chromatography, followed by TEV cleavage for His-tag removal, and size exclusion chromatography was used to prepare the ADO used for X-ray crystallography in this study. Cell pellets were resuspended in lysis buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 0.1&#x02009;&#x003bc;M CoCl<sub>2</sub>, 2.5&#x02009;mM imidazole, 10&#x02009;&#x003bc;g/ml DNAse I, 100&#x02009;&#x003bc;g/ml lysozyme, and 1x cOmplete EDTA-free protease inhibitor) and lysed by sonication before being clarified via centrifugation (17,000&#x02009;g for 30&#x02009;minutes followed by filtration through a 0.45&#x02009;&#x003bc;M membrane). The soluble fractions of cell lysates were subject to Co<sup>2+</sup>-affinity chromatography, using Talon resin (Cytiva) equilibrated in wash buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 0.1&#x02009;&#x003bc;M CoCl<sub>2</sub>, and 2.5&#x02009;mM imidazole). Bound proteins were washed and eluted with elution buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, and 300&#x02009;mM imidazole). Eluates were concurrently dialysed in SEC buffer (20&#x02009;mM HEPES pH 7.5, 150&#x02009;mM NaCl, and 1&#x02009;mM TCEP) and incubated with TEV protease overnight at 4&#x02009;&#x000b0;C to cleave the His-tag. The dialysed cleaved protein was passed through Talon resin (Cytiva) for His-tag removal before being concentrated and injected onto an equilibrated 16/600 HiLoad Superdex 75 SEC column (Cytiva). Protein was eluted from the column using SEC buffer. Protein purity was assessed by SDS-PAGE and concentrations were determined using A280 nm measurements.</p></sec><sec id="Sec14"><title>RGS5 prepared for SPR competitive experiments (pETDuet-RGS5)</title><p id="Par39">A purification procedure consisting of nickel-ion (Ni<sup>2+</sup>) affinity chromatography, followed by Ulp1 cleavage for His-SUMO-tag removal, and size exclusion chromatography was used to prepare RGS5. Cell pellets were resuspended in lysis buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, 20&#x02009;mM imidazole, 10&#x02009;&#x003bc;g/ml DNAse I, 100&#x02009;&#x003bc;g/ml lysozyme, and 1x cOmplete EDTA-free protease inhibitor) and lysed by sonication before being clarified via centrifugation (17,000&#x02009;g for 30&#x02009;minutes followed by filtration through a 0.45&#x02009;&#x003bc;M membrane). The soluble fractions of cell lysates were subject to Ni<sup>2+</sup>-affinity chromatography by incubating the supernatant with Ni-NTA agarose (Cytiva) equilibrated in wash buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, and 20&#x02009;mM imidazole). Bound proteins were washed and eluted with elution buffer (20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 1&#x02009;mM TCEP, and 500&#x02009;mM imidazole). Eluates were concurrently dialysed in SEC buffer (20&#x02009;mM HEPES pH 7.5, 150&#x02009;mM NaCl, and 1&#x02009;mM TCEP) and incubated with Ulp1 protease overnight at 4&#x02009;&#x000b0;C to cleave the His-SUMO-tag. The dialysed cleaved protein was passed through Talon resin (Cytiva) for His-SUMO-tag removal before being concentrated and injected onto an equilibrated 16/600 HiLoad Superdex 75 SEC column (Cytiva). Protein was eluted from the column using SEC buffer. Protein purity was assessed by SDS-PAGE and concentrations were determined using A280 nm measurements.</p></sec></sec><sec id="Sec15"><title>Random non-standard peptide integrated discovery (RaPID) mRNA display</title><p id="Par40">RaPID was conducted as previously described<sup><xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>. Briefly, DNA oligonucleotides comprising a T7 promoter, ribosome binding site, ATG start codon, 4&#x02013;15 NNS (N&#x02009;=&#x02009;A, C, G or T; S&#x02009;=&#x02009;C or G) codons, a TGC (Cys) codon and a 3&#x02019; fixed region encoding a Gly-Asn-Leu-Ile linker were amplified by PCR (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> for specific nucleotide sequences). The resulting DNA libraries were transcribed in vitro using T7 RNA polymerase to generate cognate mRNA libraries, which were purified by denaturing urea polyacrylamide gel electrophoresis. The libraries of different lengths were then pooled proportional to theoretical diversity to generate an RNA library. These were ligated to a puromycin linked oligonucleotide using T4 RNA ligase. Ribosomal synthesis of the macrocyclic peptide library from the puromycin-linked mRNA library was performed using the PURExpress &#x00394;RF123 kit (New England Biolabs) with RF2 and RF3 added. To allow for genetic code reprogramming, a custom &#x0201c;Solution A&#x0201d; was used supplemented with 19 amino acids (-Met) and <italic>N</italic>-chloroacetyl-L-tyrosine aminoacylated initiator tRNA as previously described<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Following translation, the ribosome was denatured by addition of EDTA, and the resulting mRNA-peptide library was reverse transcribed using RNase H- reverse transcriptase.<table-wrap id="Tab2"><label>Table 2</label><caption><p>The oligonucleotide and primer sequences used for library generation and selection</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Name</th><th>Sequence (5&#x02019; to 3&#x02019;)</th></tr></thead><tbody><tr><td>Template 4</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>4</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 5</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>5</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 6</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>6</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 7</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>7</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 8</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>8</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 9</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>9</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 10</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>10</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 11</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>11</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 12</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>12</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 13</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>13</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 14</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>14</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Template 15</td><td>TTAAGAAGGAGATATACATATG(NNS)<sub>15</sub>TGCGGTAACTTAATCTAGG</td></tr><tr><td>Forward primer</td><td>TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATATACATA</td></tr><tr><td>Reverse primer</td><td>TTTCCGCCCCCCGTCCTAGATTAAGTTACCGCA</td></tr></tbody></table></table-wrap></p><p id="Par41">The reverse transcribed peptide-mRNA libraries were panned against 200&#x02009;nM biotinylated target protein immobilised on Dynabeads M-280 streptavidin (Life Technologies) for 30&#x02009;min at 4&#x02009;&#x000b0;C. After washing with Tris buffered saline (50&#x02009;mM Tris pH 8.0, 150&#x02009;mM NaCl) containing 0.05% tween-20 (TBS-T), the fused peptide&#x02013;mRNA/cDNA was isolated from the beads by heating to 95&#x02009;&#x000b0;C for 5&#x02009;min, and cDNA was amplified by PCR, purified by ethanol precipitation and transcribed as above to produce the enriched mRNA library for the next round of selection. For the second and subsequent rounds of selection, three iterative counter-selections were used to remove peptides with affinity for the streptavidin beads. Sequencing of the final enriched cDNA was conducted using an iSeq next generation sequencer (Illumina).</p></sec><sec id="Sec16"><title>Fmoc-solid-phase peptide synthesis (SPPS)</title><p id="Par42">Please see supporting information, supplementary methods.</p></sec><sec id="Sec17"><title>Surface plasmon resonance</title><p id="Par43">SPR measurements were made using a Biacore T200 (Cytiva) instrument and data were analysed using the Biacore Insight Evaluation Software. Biotinylated-ADO was immobilised on a Biotin CAP chip (Cytiva) with a target density of &#x0223c;2500&#x02013;3000 RU and peptide/protein substrates were injected over the chip. Experiments were conducted at 4&#x02009;&#x000b0;C using both multi-cycle (fit using the equilibrium steady state affinity 1:1 binding model) and single-cycle kinetics mode (fit using a 1:1 binding model). A buffer comprising 20&#x02009;mM HEPES pH 7.5, 500&#x02009;mM NaCl, 10&#x02009;mM DTT, and 0.1% (v/v) tween-20 was used as the running buffer at a flow rate of 50&#x02009;&#x003bc;L/minute.</p></sec><sec id="Sec18"><title>Activity assay</title><p id="Par44">The enzymatic activity of ADO was examined by incubating between 0&#x02013;1000&#x02009;&#x003bc;M peptide substrates with 0.1&#x02009;&#x003bc;M ADO in a bench-top thermomixer at 37&#x02009;&#x000b0;C for 45&#x02009;seconds. Otherwise stated, the reaction buffer contained 50&#x02009;mM Tris pH 7.5, 50&#x02009;mM NaCl, and 5&#x02009;mM TCEP. The reactions were quenched by mixing the sample 1:10 with 1% formic acid (v/v).</p><p id="Par45">Peptide samples were injected onto a Chromolith&#x000ae; RP-18 Endcapped HPLC Columns (100&#x02013;2&#x02009;mm; Merck), heated to 40&#x02009;&#x000b0;C and eluted at 0.3&#x02009;ml/min using a gradient of 95% deionised water supplemented with 0.1% (v/v) formic acid to 95% acetonitrile. Oxidation was monitored by an ultra-high-performance liquid chromatography (UHPLC) mass spectrometry (MS) using ExionLC AD (Sciex) and SelexION (Sciex) mass spectrometer operated in a positive electrospray time-of-flight (&#x02009;+&#x02009;ESI-TOF) mode. Instrument parameters, data acquisition and data processing were controlled by Analyst software (Sciex). The peptide data processing was performed using Skyline software<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Turnover was quantified by comparing the areas underneath the product and substrate ions extracted from the total ion current chromatogram. All figures and parameters were generated using GraphPad Prism 9.</p></sec><sec id="Sec19"><title>X-ray crystallography</title><p id="Par46">Crystallisation of ADO-peptide complexes was performed using a sitting-drop vapour-diffusion technique. Low concentrations (~20&#x02013;50&#x02009;&#x003bc;M) of purified ADO were combined with ~1 molar equivalent of peptide (dissolved in 50&#x02009;mM Tris pH 7.5, 400&#x02009;mM NaCl) and concentrated to the levels required for crystallisation (~2&#x02013;3&#x02009;mM). Initial crystallisation trials were performed using commercial 96-well crystallisation screens (JCSG-plus, PEGRx HT and PACT Premier). ADO-peptide mixtures were dispensed into MRC two-drop chamber, 96-well crystallisation plates using a Mosquito crystallisation robot and each condition was screened at a 1:1 or 2:1 protein to precipitant ratio (maintaining a final drop volume of 300 nL). Initial hits were optimised by scaling up drop sizes and microcrystal seeding. All experiments were performed at 18&#x02009;&#x000b0;C. Protein crystals generally took days to weeks to appear. Crystals were frozen by plunge-freezing in liquid nitrogen following cryoprotection with 10% glycerol in the mother liquid from which the crystals were grown.&#x000a0;Final crystallisation conditions&#x000a0;were (1)&#x000a0;ADO CP6:&#x000a0;20% (w/v) PEG 3350 and 0.2&#x02009;M Sodium thiocyanate, (2)&#x000a0;ADO CP6-L8K-Ser:&#x000a0;20 % (w/v) PEG 3350, 0.2&#x02009;M Sodium nitrate and 0.1&#x02009;M Bis-Tris propane pH 6.5, and (3)&#x000a0;ADO CP6-L8d-Gly-Ser: 25 % (w/v) PEG 3350 and 0.1&#x02009;M BIS-Tris pH 5.5.</p><p id="Par47">X-ray diffraction data were collected from frozen crystals at the Australian Synchrotron using the Macromolecular Crystallography MX1 (bending magnet) and MX2 beamlines (microfocus) at 100&#x02009;K and a wavelength of 0.9537&#x02009;&#x000c5;<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Data were integrated using XDS and were processed further using the CCP4i suite<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. AIMLESS was used for indexing, scaling, and merging of the data and the initial phases were calculated by the molecular replacement programme PhaserMR using existing x-ray structures of ADO as the molecular replacement models (PDB: 7REI)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Manual model building was performed using COOT and refinement was performed by iterative rounds of manual building in COOT followed by refinement using Phenix<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. The quality of the final model was validated with the wwPDB server and submitted to the PDB. Structure diagrams were generated using CCP4MG<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. The data collection and refinement statistics for all structures described in this study are outlined in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>.</p></sec><sec id="Sec20"><title>Molecular dynamics</title><p id="Par48">Molecular dynamics was utilised to study the coordination bonds between the metal (Co<sup>2+</sup> or Fe<sup>2+</sup>), ligand (CP6-L8d-Gly-Ser or -Cys) or coordinated water molecule. From the original structure, the Ser to Cys ligand variant was generated using the mutation function in Maestro (Schr&#x000f6;dinger Release 2024-2: Maestro, Schr&#x000f6;dinger, LLC, New York, NY, 2024). The Co<sup>2+</sup> metal atom was changed to Fe<sup>2+</sup> manually. The crystal structures were prepared in Maestro using the Protein Preparation Wizard<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>, with all waters not within 5&#x02009;&#x000c5; of a heteroatom removed. A total of four simulations were run: cobalt-serine ligand, cobalt -cysteine ligand, iron-serine ligand and iron-cysteine ligand. The aim of the MD simulations to study the coordination bonds between the metal, ligand and coordinated water do not expect to cause major conformation changes without large perturbations. As such, enhanced sampling methods which usually introduce external potentials were not required.</p><p id="Par49">For the molecular dynamics studies, an orthorhombic solvent box filled with SPC water molecules, counter ions and additional 0.15&#x02009;M concentration of NaCl was constructed in Desmond system builder around each system&#x000a0;(Table <xref rid="Tab3" ref-type="table">3</xref>). The protein and ligands were parameterised using the OPLS4 forcefield, which has been shown to have improved accuracy in assessing protein-ligand binding<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Simulations were performed for 100&#x02009;ns both on each protein complex after standard energy minimisation and equilibration. The simulations were run at 310&#x02009;K, regulated via the Nos&#x000e9;&#x02013;Hoover thermostat and standard pressure, regulated via the MTK (Martyna-Tobias-Klein) barostat<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. Simulations were confirmed to have reached equilibrium via analysis of the root mean square deviation (RMSD) of the protein-ligand complex. All simulations were carried out in triplicate. To avoid biased or non-generalisable results caused by the initial configuration, the equilibration and productions runs were conducted with different random seed which assigned different starting Boltzmann distribution of velocities on atoms.<table-wrap id="Tab3"><label>Table 3</label><caption><p>A summary of the parameters used during MD simulations</p></caption><table frame="hsides" rules="groups"><thead><tr><th>System</th><th>Ser-Co<sup>2+</sup></th><th>Ser-Fe<sup>2+</sup></th><th>Cys-Co<sup>2+</sup></th><th>Cys-Fe<sup>2+</sup></th></tr></thead><tbody><tr><td>Simulation box dimensions (10&#x02009;&#x000c5; buffer)</td><td>68.955&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;66.128&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;90.245&#x02009;&#x000c5;</td><td>68.971&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;66.143&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;90.200&#x02009;&#x000c5;</td><td>68.954&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;66.129&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;90.242&#x02009;&#x000c5;</td><td>68.971&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;66.188&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;90.197&#x02009;&#x000c5;</td></tr><tr><td>Total number of atoms</td><td>38479</td><td>38428</td><td>38467</td><td>38455</td></tr><tr><td>Total number of water molecules</td><td>11513</td><td>11496</td><td>11509</td><td>11505</td></tr><tr><td>Salt concentration</td><td>0.15&#x02009;M NaCl</td><td>0.15&#x02009;M NaCl</td><td>0.15&#x02009;M NaCl</td><td>0.15&#x02009;M NaCl</td></tr></tbody></table></table-wrap></p><p id="Par50">MM-GBSA (Molecular mechanics with generalised Born and surface area solvation) calculations based on the equilibrium trajectory of conventional MD for the interactions between the protein-metal complex and ligand were calculated using Prime in Maestro<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup>. Every 5<sup>th</sup> frame from 50&#x02009;ns to the end of the simulation was taken for the energy calculations.</p></sec><sec id="Sec21"><title>Reporting summary</title><p id="Par51">Further information on research design is available in the&#x000a0;<xref rid="MOESM5" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2025_59960_MOESM1_ESM.pdf"><caption><p>Supporting information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2025_59960_MOESM2_ESM.pdf"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2025_59960_MOESM3_ESM.csv"><caption><p>Supplementary Dataset 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41467_2025_59960_MOESM4_ESM.csv"><caption><p>Supplementary Dataset 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41467_2025_59960_MOESM5_ESM.docx"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41467_2025_59960_MOESM6_ESM.pdf"><caption><p>Transparent Peer Review file</p></caption></media></supplementary-material>
</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Source data</title><p>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41467_2025_59960_MOESM7_ESM.xlsx"><caption><p>Source Data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41467-025-59960-3.</p></sec><ack><title>Acknowledgements</title><p>We acknowledge Sydney Analytical Core Facilities (University of Sydney) for providing access to SPR infrastructure and Sydney Mass Spectrometry (University of Sydney) for providing access to mass spectrometry infrastructure. We thank Dr Lorna Wilkinson-White and Dr Atul Bhatnager for consultation regarding SPR and mass spectrometry experiments, respectively. We thank the Structural Biology Group, School of Life and Environmental Sciences (University of Sydney), for providing access to protein production and characterisation infrastructure. We thank Prof Joel P. Mackay and Dr Leo Corcilius for discussions on the work. This research was undertaken using the MX1 and MX2 beamlines at the Australian Synchrotron, part of Australian Nuclear Science and Technology Organisation (ANSTO) and made use of the Australian Cancer Research Foundation (ACRF) detector. This work was supported by an Australian Research Council (ARC) Discovery Early Career Researcher Award (DECRA, project ID: DE190100668), a National Health and Medical Research Council (NHMRC) Investigator Grant (project ID: 2008546), and a New South Wales (NSW) Cardiovascular Research Capacity Programme Grant (project ID: EMC72) awarded to M. D. W, and the Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science (project ID: CE200100012) awarded to R. J. P.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>M.D.W. conceived and designed the study with input from all authors. Y.J., K.P., J.J-L., J.W.C.M., Y.C., J.J.D., and T.P. conducted the experimental investigation. Y.J. and K.P. performed biochemical and structural analysis. J.J-L. and J.W.C.M. performed peptide synthesis. Y.C. and J.J.D. performed MD simulations. T.P. performed mRNA display. All authors analysed data and generated figures. M.D.W. and R.J.P. acquired funding. M.D.W., R.J.P., K.M.C., and J.J.D. provided supervision. M.D.W. wrote the manuscript with input from all authors.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par52"><italic>Nature Communications</italic> thanks Hyun Kyu Song and the other, anonymous, reviewers for their contribution to the peer review of this work. A peer review file is available.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>The coordinates of cobalt-incorporated ADO in complex with CP6 were deposited to the Protein Data Bank (PDB) under accession code <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb9DXU/pdb">9DXU</ext-link>. The coordinates of cobalt-incorporated ADO in complex with CP6-L8K-Ser were deposited to the PDB under accession code <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb9DXV/pdb">9DXV</ext-link>. The coordinates of cobalt-incorporated ADO in complex with CP6-L8d-Gly-Ser were deposited to the PDB under accession code <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb9DXB/pdb">9DXB</ext-link>. The coordinates of cobalt-incorporated ADO in the absence of a CP were obtained from the PDB using accession code <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb8UAN/pdb">8UAN</ext-link>. The coordinates of iron-incorporated CDO in complex with Cys were obtained from the PDB using accession code <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb4IEV/pdb">4IEV</ext-link>.&#x000a0;<xref ref-type="sec" rid="Sec23">Source data</xref> are provided with this paper.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par53">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name></person-group><article-title>Cellular adaptation to hypoxia through hypoxia inducible factors and beyond</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2020</year><volume>21</volume><fpage>268</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0227-y</pub-id><pub-id pub-id-type="pmid">32144406</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lee, P., Chandel, N. S. &#x00026; Simon, M. C. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. <italic>Nat. Rev. Mol. Cell Biol.</italic><bold>21</bold>, 268&#x02013;283 (2020).<pub-id pub-id-type="pmid">32144406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Pathophysiological implications of hypoxia in human diseases</article-title><source>J. Biomed. Sci.</source><year>2020</year><volume>27</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12929-020-00658-7</pub-id><pub-id pub-id-type="pmid">32389123</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chen, P. S. et al. Pathophysiological implications of hypoxia in human diseases. <italic>J. Biomed. Sci.</italic><bold>27</bold>, 63 (2020).<pub-id pub-id-type="pmid">32389123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials</article-title><source>Chem. Sci.</source><year>2017</year><volume>8</volume><fpage>7651</fpage><lpage>7668</lpage><pub-id pub-id-type="doi">10.1039/C7SC02103H</pub-id><pub-id pub-id-type="pmid">29435217</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Yeh, T. L. et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. <italic>Chem. Sci.</italic><bold>8</bold>, 7651&#x02013;7668 (2017).<pub-id pub-id-type="pmid">29435217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases</article-title><source>Front Pharm.</source><year>2022</year><volume>13</volume><fpage>837249</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.837249</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Miao, M. et al. Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases. <italic>Front Pharm.</italic><bold>13</bold>, 837249 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group><article-title>Belzutifan: first approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>1921</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01606-x</pub-id><pub-id pub-id-type="pmid">34613603</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Deeks, E. D. Belzutifan: first approval. <italic>Drugs</italic><bold>81</bold>, 1921&#x02013;1927 (2021).<pub-id pub-id-type="pmid">34613603</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelin</surname><given-names>WG</given-names><suffix>Jr</suffix></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name></person-group><article-title>Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway</article-title><source>Mol. Cell</source><year>2008</year><volume>30</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.04.009</pub-id><pub-id pub-id-type="pmid">18498744</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kaelin, W. G. Jr &#x00026; Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. <italic>Mol. Cell</italic><bold>30</bold>, 393&#x02013;402 (2008).<pub-id pub-id-type="pmid">18498744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>N</given-names></name><etal/></person-group><article-title>Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants</article-title><source>Science</source><year>2019</year><volume>365</volume><fpage>65</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1126/science.aaw0112</pub-id><pub-id pub-id-type="pmid">31273118</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Masson, N. et al. Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants. <italic>Science</italic><bold>365</bold>, 65&#x02013;69 (2019).<pub-id pub-id-type="pmid">31273118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group><article-title>N-degron pathways</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2024</year><volume>121</volume><fpage>e2408697121</fpage><pub-id pub-id-type="doi">10.1073/pnas.2408697121</pub-id><pub-id pub-id-type="pmid">39264755</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Varshavsky, A. N-degron pathways. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>121</bold>, e2408697121 (2024).<pub-id pub-id-type="pmid">39264755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Plant cysteine oxidases are dioxygenases that directly enable arginyl transferase-catalysed arginylation of N-end rule targets</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>14690</fpage><pub-id pub-id-type="doi">10.1038/ncomms14690</pub-id><pub-id pub-id-type="pmid">28332493</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">White, M. D. et al. Plant cysteine oxidases are dioxygenases that directly enable arginyl transferase-catalysed arginylation of N-end rule targets. <italic>Nat. Commun.</italic><bold>8</bold>, 14690 (2017).<pub-id pub-id-type="pmid">28332493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Weits</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Plant cysteine oxidases control the oxygen-dependent branch of the N-end-rule pathway</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3425</fpage><pub-id pub-id-type="doi">10.1038/ncomms4425</pub-id><pub-id pub-id-type="pmid">24599061</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Weits, D. A. et al. Plant cysteine oxidases control the oxygen-dependent branch of the N-end-rule pathway. <italic>Nat. Commun.</italic><bold>5</bold>, 3425 (2014).<pub-id pub-id-type="pmid">24599061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>MD</given-names></name><name><surname>Kamps</surname><given-names>J</given-names></name><name><surname>East</surname><given-names>S</given-names></name><name><surname>Taylor Kearney</surname><given-names>LJ</given-names></name><name><surname>Flashman</surname><given-names>E</given-names></name></person-group><article-title>The plant cysteine oxidases from Arabidopsis thaliana are kinetically tailored to act as oxygen sensors</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>11786</fpage><lpage>11795</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.003496</pub-id><pub-id pub-id-type="pmid">29848548</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">White, M. D., Kamps, J., East, S., Taylor Kearney, L. J. &#x00026; Flashman, E. The plant cysteine oxidases from Arabidopsis thaliana are kinetically tailored to act as oxygen sensors. <italic>J. Biol. Chem.</italic><bold>293</bold>, 11786&#x02013;11795 (2018).<pub-id pub-id-type="pmid">29848548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Dominy</surname><given-names>JE</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>25189</fpage><lpage>25198</lpage><pub-id pub-id-type="doi">10.1074/jbc.M703089200</pub-id><pub-id pub-id-type="pmid">17581819</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dominy, J. E. Jr et al. Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase. <italic>J. Biol. Chem.</italic><bold>282</bold>, 25189&#x02013;25198 (2007).<pub-id pub-id-type="pmid">17581819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>YM</given-names></name><name><surname>Holdship</surname><given-names>P</given-names></name><name><surname>To</surname><given-names>TQ</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Keeley</surname><given-names>TP</given-names></name></person-group><article-title>Comparative analysis of N-terminal cysteine dioxygenation and prolyl-hydroxylation as oxygen-sensing pathways in mammalian cells</article-title><source>J. Biol. Chem.</source><year>2023</year><volume>299</volume><fpage>105156</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2023.105156</pub-id><pub-id pub-id-type="pmid">37572852</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tian, Y. M., Holdship, P., To, T. Q., Ratcliffe, P. J. &#x00026; Keeley, T. P. Comparative analysis of N-terminal cysteine dioxygenation and prolyl-hydroxylation as oxygen-sensing pathways in mammalian cells. <italic>J. Biol. Chem.</italic><bold>299</bold>, 105156 (2023).<pub-id pub-id-type="pmid">37572852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>RGS4 and RGS5 are in vivo substrates of the N-end rule pathway</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>15030</fpage><lpage>15035</lpage><pub-id pub-id-type="doi">10.1073/pnas.0507533102</pub-id><pub-id pub-id-type="pmid">16217033</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lee, M. J. et al. RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>102</bold>, 15030&#x02013;15035 (2005).<pub-id pub-id-type="pmid">16217033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Nold-Petry</surname><given-names>CA</given-names></name><etal/></person-group><article-title>IL-32 promotes angiogenesis</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>589</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202802</pub-id><pub-id pub-id-type="pmid">24337385</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Nold-Petry, C. A. et al. IL-32 promotes angiogenesis. <italic>J. Immunol.</italic><bold>192</bold>, 589&#x02013;602 (2014).<pub-id pub-id-type="pmid">24337385</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamzah</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vascular normalization in Rgs5-deficient tumours promotes immune destruction</article-title><source>Nature</source><year>2008</year><volume>453</volume><fpage>410</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nature06868</pub-id><pub-id pub-id-type="pmid">18418378</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. <italic>Nature</italic><bold>453</bold>, 410&#x02013;414 (2008).<pub-id pub-id-type="pmid">18418378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>N</given-names></name></person-group><article-title>Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>78530</fpage><lpage>78544</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20825</pub-id><pub-id pub-id-type="pmid">29108247</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Xue, X., Wang, L., Meng, X., Jiao, J. &#x00026; Dang, N. Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway. <italic>Oncotarget</italic><bold>8</bold>, 78530&#x02013;78544 (2017).<pub-id pub-id-type="pmid">29108247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4</article-title><source>Cancer Res.</source><year>2009</year><volume>69</volume><fpage>5743</fpage><lpage>5751</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3564</pub-id><pub-id pub-id-type="pmid">19549919</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Xie, Y. et al. Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. <italic>Cancer Res.</italic><bold>69</bold>, 5743&#x02013;5751 (2009).<pub-id pub-id-type="pmid">19549919</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Weiler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.137</pub-id><pub-id pub-id-type="pmid">22562250</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Weiler, M. et al. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. <italic>Oncogene</italic><bold>32</bold>, 1099&#x02013;1109 (2013).<pub-id pub-id-type="pmid">22562250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Kastnes</surname><given-names>M</given-names></name><etal/></person-group><article-title>The pro-tumorigenic cytokine IL-32 has a high turnover in multiple myeloma cells due to proteolysis regulated by oxygen-sensing cysteine dioxygenase and deubiquitinating enzymes</article-title><source>Front Oncol.</source><year>2023</year><volume>13</volume><fpage>1197542</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1197542</pub-id><pub-id pub-id-type="pmid">37313466</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kastnes, M. et al. The pro-tumorigenic cytokine IL-32 has a high turnover in multiple myeloma cells due to proteolysis regulated by oxygen-sensing cysteine dioxygenase and deubiquitinating enzymes. <italic>Front Oncol.</italic><bold>13</bold>, 1197542 (2023).<pub-id pub-id-type="pmid">37313466</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Sloot</surname><given-names>YJE</given-names></name><name><surname>Smit</surname><given-names>JW</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Netea-Maier</surname><given-names>RT</given-names></name></person-group><article-title>Insights into the role of IL-32 in cancer</article-title><source>Semin Immunol.</source><year>2018</year><volume>38</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2018.03.004</pub-id><pub-id pub-id-type="pmid">29747940</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sloot, Y. J. E. Smit, J. W., Joosten, L. A. B. &#x00026; Netea-Maier, R. T. Insights into the role of IL-32 in cancer. <italic>Semin Immunol.</italic><bold>38</bold>, 24&#x02013;32 (2018).<pub-id pub-id-type="pmid">29747940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Kearney, C. J. et al. Tumor immune evasion arises through loss of TNF sensitivity. <italic>Sci Immunol</italic><bold>3</bold>, eaar3451 (2018).</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SCS</given-names></name><etal/></person-group><article-title>Cysteamine dioxygenase (ADO) governs cancer cell mitochondrial redox homeostasis through proline metabolism</article-title><source>Sci. Adv.</source><year>2024</year><volume>10</volume><fpage>eadq0355</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adq0355</pub-id><pub-id pub-id-type="pmid">39356760</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lee, S. C. S. et al. Cysteamine dioxygenase (ADO) governs cancer cell mitochondrial redox homeostasis through proline metabolism. <italic>Sci. Adv.</italic><bold>10</bold>, eadq0355 (2024).<pub-id pub-id-type="pmid">39356760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>RL</given-names></name><etal/></person-group><article-title>The crystal structure of cysteamine dioxygenase reveals the origin of the large substrate scope of this vital mammalian enzyme</article-title><source>Biochemistry</source><year>2021</year><volume>60</volume><fpage>3728</fpage><lpage>3737</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.1c00463</pub-id><pub-id pub-id-type="pmid">34762398</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Fernandez, R. L. et al. The crystal structure of cysteamine dioxygenase reveals the origin of the large substrate scope of this vital mammalian enzyme. <italic>Biochemistry</italic><bold>60</bold>, 3728&#x02013;3737 (2021).<pub-id pub-id-type="pmid">34762398</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name></person-group><article-title>Crystal structure of human cysteamine dioxygenase provides a structural rationale for its function as an oxygen sensor</article-title><source>J. Biol. Chem.</source><year>2021</year><volume>297</volume><fpage>101176</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101176</pub-id><pub-id pub-id-type="pmid">34508780</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wang, Y., Shin, I., Li, J. &#x00026; Liu, A. Crystal structure of human cysteamine dioxygenase provides a structural rationale for its function as an oxygen sensor. <italic>J. Biol. Chem.</italic><bold>297</bold>, 101176 (2021).<pub-id pub-id-type="pmid">34508780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Stipanuk</surname><given-names>MH</given-names></name><name><surname>Ueki</surname><given-names>I</given-names></name><name><surname>Dominy</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Simmons</surname><given-names>CR</given-names></name><name><surname>Hirschberger</surname><given-names>LL</given-names></name></person-group><article-title>Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels</article-title><source>Amino Acids</source><year>2009</year><volume>37</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s00726-008-0202-y</pub-id><pub-id pub-id-type="pmid">19011731</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Stipanuk, M. H., Ueki, I., Dominy, J. E. Jr, Simmons, C. R. &#x00026; Hirschberger, L. L. Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. <italic>Amino Acids</italic><bold>37</bold>, 55&#x02013;63 (2009).<pub-id pub-id-type="pmid">19011731</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Driggers</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Cysteine dioxygenase structures from pH4 to 9: consistent cys-persulfenate formation at intermediate pH and a Cys-bound enzyme at higher pH</article-title><source>J. Mol. Biol.</source><year>2013</year><volume>425</volume><fpage>3121</fpage><lpage>3136</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2013.05.028</pub-id><pub-id pub-id-type="pmid">23747973</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Driggers, C. M. et al. Cysteine dioxygenase structures from pH4 to 9: consistent cys-persulfenate formation at intermediate pH and a Cys-bound enzyme at higher pH. <italic>J. Mol. Biol.</italic><bold>425</bold>, 3121&#x02013;3136 (2013).<pub-id pub-id-type="pmid">23747973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cleavage of a carbon-fluorine bond by an engineered cysteine dioxygenase</article-title><source>Nat. Chem. Biol.</source><year>2018</year><volume>14</volume><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0085-5</pub-id><pub-id pub-id-type="pmid">29942080</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Li, J. et al. Cleavage of a carbon-fluorine bond by an engineered cysteine dioxygenase. <italic>Nat. Chem. Biol.</italic><bold>14</bold>, 853&#x02013;860 (2018).<pub-id pub-id-type="pmid">29942080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>CR</given-names></name><etal/></person-group><article-title>A putative Fe2+-bound persulfenate intermediate in cysteine dioxygenase</article-title><source>Biochemistry</source><year>2008</year><volume>47</volume><fpage>11390</fpage><lpage>11392</lpage><pub-id pub-id-type="doi">10.1021/bi801546n</pub-id><pub-id pub-id-type="pmid">18847220</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Simmons, C. R. et al. A putative Fe2+-bound persulfenate intermediate in cysteine dioxygenase. <italic>Biochemistry</italic><bold>47</bold>, 11390&#x02013;11392 (2008).<pub-id pub-id-type="pmid">18847220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>AA</given-names></name><name><surname>Lindeman</surname><given-names>SV</given-names></name><name><surname>Fiedler</surname><given-names>AT</given-names></name></person-group><article-title>A synthetic model of the nonheme iron-superoxo intermediate of cysteine dioxygenase</article-title><source>Chem. Commun. (Camb.)</source><year>2018</year><volume>54</volume><fpage>11344</fpage><lpage>11347</lpage><pub-id pub-id-type="doi">10.1039/C8CC06247A</pub-id><pub-id pub-id-type="pmid">30246208</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Fischer, A. A., Lindeman, S. V. &#x00026; Fiedler, A. T. A synthetic model of the nonheme iron-superoxo intermediate of cysteine dioxygenase. <italic>Chem. Commun. (Camb.)</italic><bold>54</bold>, 11344&#x02013;11347 (2018).<pub-id pub-id-type="pmid">30246208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Blaesi</surname><given-names>EJ</given-names></name><name><surname>Fox</surname><given-names>BG</given-names></name><name><surname>Brunold</surname><given-names>TC</given-names></name></person-group><article-title>Spectroscopic and computational investigation of iron(III) cysteine dioxygenase: implications for the nature of the putative superoxo-Fe(III) intermediate</article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>5759</fpage><lpage>5770</lpage><pub-id pub-id-type="doi">10.1021/bi500767x</pub-id><pub-id pub-id-type="pmid">25093959</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Blaesi, E. J., Fox, B. G. &#x00026; Brunold, T. C. Spectroscopic and computational investigation of iron(III) cysteine dioxygenase: implications for the nature of the putative superoxo-Fe(III) intermediate. <italic>Biochemistry</italic><bold>53</bold>, 5759&#x02013;5770 (2014).<pub-id pub-id-type="pmid">25093959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Characterization of the nonheme iron center of cysteamine dioxygenase and its interaction with substrates</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>11789</fpage><lpage>11802</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013915</pub-id><pub-id pub-id-type="pmid">32601061</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wang, Y. et al. Characterization of the nonheme iron center of cysteamine dioxygenase and its interaction with substrates. <italic>J. Biol. Chem.</italic><bold>295</bold>, 11789&#x02013;11802 (2020).<pub-id pub-id-type="pmid">32601061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>RL</given-names></name><name><surname>Dillon</surname><given-names>SL</given-names></name><name><surname>Stipanuk</surname><given-names>MH</given-names></name><name><surname>Fox</surname><given-names>BG</given-names></name><name><surname>Brunold</surname><given-names>TC</given-names></name></person-group><article-title>Spectroscopic investigation of cysteamine dioxygenase</article-title><source>Biochemistry</source><year>2020</year><volume>59</volume><fpage>2450</fpage><lpage>2458</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.0c00267</pub-id><pub-id pub-id-type="pmid">32510930</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fernandez, R. L., Dillon, S. L., Stipanuk, M. H., Fox, B. G. &#x00026; Brunold, T. C. Spectroscopic investigation of cysteamine dioxygenase. <italic>Biochemistry</italic><bold>59</bold>, 2450&#x02013;2458 (2020).<pub-id pub-id-type="pmid">32510930</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name></person-group><article-title>Cobalt(II)-substituted cysteamine dioxygenase oxygenation proceeds through a cobalt(III)-superoxo complex</article-title><source>J. Am. Chem. Soc.</source><year>2024</year><volume>146</volume><fpage>18292</fpage><lpage>18297</lpage><pub-id pub-id-type="doi">10.1021/jacs.4c01871</pub-id><pub-id pub-id-type="pmid">38941563</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Li, J., Duan, R. &#x00026; Liu, A. Cobalt(II)-substituted cysteamine dioxygenase oxygenation proceeds through a cobalt(III)-superoxo complex. <italic>J. Am. Chem. Soc.</italic><bold>146</bold>, 18292&#x02013;18297 (2024).<pub-id pub-id-type="pmid">38941563</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Heathcote</surname><given-names>KC</given-names></name><etal/></person-group><article-title>N-terminal cysteine acetylation and oxidation patterns may define protein stability</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>5360</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49489-2</pub-id><pub-id pub-id-type="pmid">38918375</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Heathcote, K. C. et al. N-terminal cysteine acetylation and oxidation patterns may define protein stability. <italic>Nat. Commun.</italic><bold>15</bold>, 5360 (2024).<pub-id pub-id-type="pmid">38918375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K</given-names></name><etal/></person-group><article-title>The enzymatic oxygen sensor cysteamine dioxygenase binds its protein substrates through their N-termini</article-title><source>J. Biol. Chem.</source><year>2024</year><volume>300</volume><fpage>107653</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2024.107653</pub-id><pub-id pub-id-type="pmid">39122008</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Patel, K. et al. The enzymatic oxygen sensor cysteamine dioxygenase binds its protein substrates through their N-termini. <italic>J. Biol. Chem.</italic><bold>300</bold>, 107653 (2024).<pub-id pub-id-type="pmid">39122008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen-Leete</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antiviral cyclic peptides targeting the main protease of SARS-CoV-2</article-title><source>Chem. Sci.</source><year>2022</year><volume>13</volume><fpage>3826</fpage><lpage>3836</lpage><pub-id pub-id-type="doi">10.1039/D1SC06750H</pub-id><pub-id pub-id-type="pmid">35432913</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Johansen-Leete, J. et al. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. <italic>Chem. Sci.</italic><bold>13</bold>, 3826&#x02013;3836 (2022).<pub-id pub-id-type="pmid">35432913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cyclic peptides can engage a single binding pocket through highly divergent modes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>26728</fpage><lpage>26738</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003086117</pub-id><pub-id pub-id-type="pmid">33046654</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Patel, K. et al. Cyclic peptides can engage a single binding pocket through highly divergent modes. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>117</bold>, 26728&#x02013;26738 (2020).<pub-id pub-id-type="pmid">33046654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Bedding</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Discovery of high affinity cyclic peptide ligands for human ACE2 with SARS-CoV-2 entry inhibitory activity</article-title><source>ACS Chem. Biol.</source><year>2024</year><volume>19</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1021/acschembio.3c00568</pub-id><pub-id pub-id-type="pmid">38085789</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Bedding, M. J. et al. Discovery of high affinity cyclic peptide ligands for human ACE2 with SARS-CoV-2 entry inhibitory activity. <italic>ACS Chem. Biol.</italic><bold>19</bold>, 141&#x02013;152 (2024).<pub-id pub-id-type="pmid">38085789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Discovery of cyclic peptide ligands to the SARS-CoV-2 spike protein using mRNA display</article-title><source>ACS Cent. Sci.</source><year>2021</year><volume>7</volume><fpage>1001</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.0c01708</pub-id><pub-id pub-id-type="pmid">34230894</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Norman, A. et al. Discovery of cyclic peptide ligands to the SARS-CoV-2 spike protein using mRNA display. <italic>ACS Cent. Sci.</italic><bold>7</bold>, 1001&#x02013;1008 (2021).<pub-id pub-id-type="pmid">34230894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>CMH</given-names></name><name><surname>Pinto</surname><given-names>ISS</given-names></name><name><surname>Soares</surname><given-names>EV</given-names></name><collab>Soares HMVM.</collab></person-group><article-title>Unsuitability of the use of ph buffers in biological, biochemical and environmental studies and their interaction with metal ions&#x02013;a review.</article-title><source>RSC Advances</source><year>2015</year><volume>5</volume><fpage>30989</fpage><lpage>31003</lpage><pub-id pub-id-type="doi">10.1039/C4RA15453C</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Ferreira, C. M. H., Pinto, I. S. S. &#x00026; Soares, E. V. Soares HMVM. Unsuitability of the use of ph buffers in biological, biochemical and environmental studies and their interaction with metal ions&#x02013;a review.<italic>RSC Advances</italic><bold>5</bold>, 30989&#x02013;31003 (2015).</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Molecular basis for cysteine oxidation by plant cysteine oxidases from Arabidopsis thaliana</article-title><source>J. Struct. Biol.</source><year>2021</year><volume>213</volume><fpage>107663</fpage><pub-id pub-id-type="doi">10.1016/j.jsb.2020.107663</pub-id><pub-id pub-id-type="pmid">33207269</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Chen, Z. et al. Molecular basis for cysteine oxidation by plant cysteine oxidases from Arabidopsis thaliana. <italic>J. Struct. Biol.</italic><bold>213</bold>, 107663 (2021).<pub-id pub-id-type="pmid">33207269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Structures of Arabidopsis thaliana oxygen-sensing plant cysteine oxidases 4 and 5 enable targeted manipulation of their activity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>23140</fpage><lpage>23147</lpage><pub-id pub-id-type="doi">10.1073/pnas.2000206117</pub-id><pub-id pub-id-type="pmid">32868422</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">White, M. D. et al. Structures of Arabidopsis thaliana oxygen-sensing plant cysteine oxidases 4 and 5 enable targeted manipulation of their activity. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>117</bold>, 23140&#x02013;23147 (2020).<pub-id pub-id-type="pmid">32868422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Unusual catalytic strategy by non-heme Fe(ii)/2-oxoglutarate-dependent aspartyl hydroxylase AspH</article-title><source>Chem. Sci.</source><year>2024</year><volume>15</volume><fpage>3466</fpage><lpage>3484</lpage><pub-id pub-id-type="doi">10.1039/D3SC05974J</pub-id><pub-id pub-id-type="pmid">38455014</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Krishnan, A. et al. Unusual catalytic strategy by non-heme Fe(ii)/2-oxoglutarate-dependent aspartyl hydroxylase AspH. <italic>Chem. Sci.</italic><bold>15</bold>, 3466&#x02013;3484 (2024).<pub-id pub-id-type="pmid">38455014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorini</surname><given-names>G</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name></person-group><article-title>Biochemistry of the hypoxia-inducible factor hydroxylases</article-title><source>Curr. Opin. Chem. Biol.</source><year>2024</year><volume>79</volume><fpage>102428</fpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2024.102428</pub-id><pub-id pub-id-type="pmid">38330792</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Fiorini, G. &#x00026; Schofield, C. J. Biochemistry of the hypoxia-inducible factor hydroxylases. <italic>Curr. Opin. Chem. Biol.</italic><bold>79</bold>, 102428 (2024).<pub-id pub-id-type="pmid">38330792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>MD</given-names></name><name><surname>Flashman</surname><given-names>E</given-names></name></person-group><article-title>Catalytic strategies of the non-heme iron dependent oxygenases and their roles in plant biology</article-title><source>Curr. Opin. Chem. Biol.</source><year>2016</year><volume>31</volume><fpage>126</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2016.02.017</pub-id><pub-id pub-id-type="pmid">27015291</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">White, M. D. &#x00026; Flashman, E. Catalytic strategies of the non-heme iron dependent oxygenases and their roles in plant biology. <italic>Curr. Opin. Chem. Biol.</italic><bold>31</bold>, 126&#x02013;135 (2016).<pub-id pub-id-type="pmid">27015291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Blaesi</surname><given-names>EJ</given-names></name><name><surname>Pecore</surname><given-names>MD</given-names></name><name><surname>Crowell</surname><given-names>JK</given-names></name><name><surname>Pierce</surname><given-names>BS</given-names></name></person-group><article-title>Second-Sphere Interactions between the C93&#x02013;Y157 cross-link and the substrate-bound Fe site influence the O<sub>2</sub> coupling efficiency in mouse cysteine dioxygenase</article-title><source>Biochemistry</source><year>2013</year><volume>52</volume><fpage>9104</fpage><lpage>9119</lpage><pub-id pub-id-type="doi">10.1021/bi4010232</pub-id><pub-id pub-id-type="pmid">24279989</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Li, W., Blaesi, E. J., Pecore, M. D., Crowell, J. K. &#x00026; Pierce, B. S. Second-Sphere Interactions between the C93&#x02013;Y157 cross-link and the substrate-bound Fe site influence the O<sub>2</sub> coupling efficiency in mouse cysteine dioxygenase. <italic>Biochemistry</italic><bold>52</bold>, 9104&#x02013;9119 (2013).<pub-id pub-id-type="pmid">24279989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Driggers</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Structure-based insights into the role of the Cys&#x02013;Tyr crosslink and inhibitor recognition by mammalian cysteine dioxygenase</article-title><source>J. Mol. Biol.</source><year>2016</year><volume>428</volume><fpage>3999</fpage><lpage>4012</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2016.07.012</pub-id><pub-id pub-id-type="pmid">27477048</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Driggers, C. M. et al. Structure-based insights into the role of the Cys&#x02013;Tyr crosslink and inhibitor recognition by mammalian cysteine dioxygenase. <italic>J. Mol. Biol.</italic><bold>428</bold>, 3999&#x02013;4012 (2016).<pub-id pub-id-type="pmid">27477048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Improved resolution of 3-mercaptopropionate dioxygenase active site provided by ENDOR spectroscopy offers insight into catalytic mechanism</article-title><source>J. Biol. Chem.</source><year>2024</year><volume>300</volume><fpage>105777</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2024.105777</pub-id><pub-id pub-id-type="pmid">38395308</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Pierce, B. S. et al. Improved resolution of 3-mercaptopropionate dioxygenase active site provided by ENDOR spectroscopy offers insight into catalytic mechanism. <italic>J. Biol. Chem.</italic><bold>300</bold>, 105777 (2024).<pub-id pub-id-type="pmid">38395308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Lavilla-Puerta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of novel plant cysteine oxidase inhibitors from a yeast chemical genetic screen</article-title><source>J. Biol. Chem.</source><year>2023</year><volume>299</volume><fpage>105366</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2023.105366</pub-id><pub-id pub-id-type="pmid">37863264</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Lavilla-Puerta, M. et al. Identification of novel plant cysteine oxidase inhibitors from a yeast chemical genetic screen. <italic>J. Biol. Chem.</italic><bold>299</bold>, 105366 (2023).<pub-id pub-id-type="pmid">37863264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Mendiondo</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Enhanced waterlogging tolerance in barley by manipulation of expression of the N-end rule pathway E3 ligase PROTEOLYSIS6</article-title><source>Plant Biotechnol. J.</source><year>2016</year><volume>14</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1111/pbi.12334</pub-id><pub-id pub-id-type="pmid">25657015</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Mendiondo, G. M. et al. Enhanced waterlogging tolerance in barley by manipulation of expression of the N-end rule pathway E3 ligase PROTEOLYSIS6. <italic>Plant Biotechnol. J.</italic><bold>14</bold>, 40&#x02013;50 (2016).<pub-id pub-id-type="pmid">25657015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Regulatory cascade involving transcriptional and N-end rule pathways in rice under submergence</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>3300</fpage><lpage>3309</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818507116</pub-id><pub-id pub-id-type="pmid">30723146</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Lin, C. C. et al. Regulatory cascade involving transcriptional and N-end rule pathways in rice under submergence. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>116</bold>, 3300&#x02013;3309 (2019).<pub-id pub-id-type="pmid">30723146</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Katoh</surname><given-names>T</given-names></name><name><surname>Suga</surname><given-names>H</given-names></name></person-group><article-title>Flexizymes for genetic code reprogramming</article-title><source>Nat. Protoc.</source><year>2011</year><volume>6</volume><fpage>779</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1038/nprot.2011.331</pub-id><pub-id pub-id-type="pmid">21637198</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Goto, Y., Katoh, T. &#x00026; Suga, H. Flexizymes for genetic code reprogramming. <italic>Nat. Protoc.</italic><bold>6</bold>, 779&#x02013;790 (2011).<pub-id pub-id-type="pmid">21637198</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>B</given-names></name><etal/></person-group><article-title>Skyline: an open source document editor for creating and analyzing targeted proteomics experiments</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>966</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq054</pub-id><pub-id pub-id-type="pmid">20147306</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. <italic>Bioinformatics</italic><bold>26</bold>, 966&#x02013;968 (2010).<pub-id pub-id-type="pmid">20147306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Cowieson</surname><given-names>NP</given-names></name><etal/></person-group><article-title>MX1: a bending-magnet crystallography beamline serving both chemical and macromolecular crystallography communities at the Australian Synchrotron</article-title><source>J. Synchrotron Radiat.</source><year>2015</year><volume>22</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1107/S1600577514021717</pub-id><pub-id pub-id-type="pmid">25537608</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Cowieson, N. P. et al. MX1: a bending-magnet crystallography beamline serving both chemical and macromolecular crystallography communities at the Australian Synchrotron. <italic>J. Synchrotron Radiat.</italic><bold>22</bold>, 187&#x02013;190 (2015).<pub-id pub-id-type="pmid">25537608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Aragao</surname><given-names>D</given-names></name><etal/></person-group><article-title>MX2: a high-flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian synchrotron</article-title><source>J. Synchrotron Radiat.</source><year>2018</year><volume>25</volume><fpage>885</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1107/S1600577518003120</pub-id><pub-id pub-id-type="pmid">29714201</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Aragao, D. et al. MX2: a high-flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian synchrotron. <italic>J. Synchrotron Radiat.</italic><bold>25</bold>, 885&#x02013;891 (2018).<pub-id pub-id-type="pmid">29714201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Winn</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Overview of the CCP4 suite and current developments</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><year>2011</year><volume>67</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1107/S0907444910045749</pub-id><pub-id pub-id-type="pmid">21460441</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Winn, M. D. et al. Overview of the CCP4 suite and current developments. <italic>Acta Crystallogr D. Biol. Crystallogr</italic><bold>67</bold>, 235&#x02013;242 (2011).<pub-id pub-id-type="pmid">21460441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Potterton</surname><given-names>E</given-names></name><name><surname>Briggs</surname><given-names>P</given-names></name><name><surname>Turkenburg</surname><given-names>M</given-names></name><name><surname>Dodson</surname><given-names>E</given-names></name></person-group><article-title>A graphical user interface to the CCP4 program suite</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><year>2003</year><volume>59</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1107/S0907444903008126</pub-id><pub-id pub-id-type="pmid">12832755</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Potterton, E., Briggs, P., Turkenburg, M. &#x00026; Dodson, E. A graphical user interface to the CCP4 program suite. <italic>Acta Crystallogr D. Biol. Crystallogr</italic><bold>59</bold>, 1131&#x02013;1137 (2003).<pub-id pub-id-type="pmid">12832755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><year>2010</year><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Emsley, P., Lohkamp, B., Scott, W. G. &#x00026; Cowtan, K. Features and development of Coot. <italic>Acta Crystallogr D. Biol. Crystallogr</italic><bold>66</bold>, 486&#x02013;501 (2010).<pub-id pub-id-type="pmid">20383002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><etal/></person-group><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><year>2010</year><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. <italic>Acta Crystallogr D. Biol. Crystallogr</italic><bold>66</bold>, 213&#x02013;221 (2010).<pub-id pub-id-type="pmid">20124702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>McNicholas</surname><given-names>S</given-names></name><name><surname>Potterton</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>KS</given-names></name><name><surname>Noble</surname><given-names>ME</given-names></name></person-group><article-title>Presenting your structures: the CCP4mg molecular-graphics software</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><year>2011</year><volume>67</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1107/S0907444911007281</pub-id><pub-id pub-id-type="pmid">21460457</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">McNicholas, S., Potterton, E., Wilson, K. S. &#x00026; Noble, M. E. Presenting your structures: the CCP4mg molecular-graphics software. <italic>Acta Crystallogr D. Biol. Crystallogr</italic><bold>67</bold>, 386&#x02013;394 (2011).<pub-id pub-id-type="pmid">21460457</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>GM</given-names></name><name><surname>Adzhigirey</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>T</given-names></name><name><surname>Annabhimoju</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>W</given-names></name></person-group><article-title>Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</article-title><source>J. Comput Aided Mol. Des.</source><year>2013</year><volume>27</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s10822-013-9644-8</pub-id><pub-id pub-id-type="pmid">23579614</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. &#x00026; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. <italic>J. Comput Aided Mol. Des.</italic><bold>27</bold>, 221&#x02013;234 (2013).<pub-id pub-id-type="pmid">23579614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><etal/></person-group><article-title>OPLS4: improving force field accuracy on challenging regimes of chemical space</article-title><source>J. Chem. Theory Comput</source><year>2021</year><volume>17</volume><fpage>4291</fpage><lpage>4300</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.1c00302</pub-id><pub-id pub-id-type="pmid">34096718</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Lu, C. et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. <italic>J. Chem. Theory Comput</italic><bold>17</bold>, 4291&#x02013;4300 (2021).<pub-id pub-id-type="pmid">34096718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DJ</given-names></name><name><surname>Holian</surname><given-names>BL</given-names></name></person-group><article-title>The Nose&#x02013;Hoover thermostat</article-title><source>J. Chem. Phys.</source><year>1985</year><volume>83</volume><fpage>4069</fpage><lpage>4074</lpage><pub-id pub-id-type="doi">10.1063/1.449071</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Evans, D. J. &#x00026; Holian, B. L. The Nose&#x02013;Hoover thermostat. <italic>J. Chem. Phys.</italic><bold>83</bold>, 4069&#x02013;4074 (1985).</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Martyna</surname><given-names>GJ</given-names></name><name><surname>Tobias</surname><given-names>DJ</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><article-title>Constant pressure molecular dynamics algorithms</article-title><source>J. Chem. Phys.</source><year>1994</year><volume>101</volume><fpage>4177</fpage><lpage>4189</lpage><pub-id pub-id-type="doi">10.1063/1.467468</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Martyna, G. J., Tobias, D. J. &#x00026; Klein, M. L. Constant pressure molecular dynamics algorithms. <italic>J. Chem. Phys.</italic><bold>101</bold>, 4177&#x02013;4189 (1994).</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>MP</given-names></name><etal/></person-group><article-title>A hierarchical approach to all-atom protein loop prediction</article-title><source>Proteins</source><year>2004</year><volume>55</volume><fpage>351</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1002/prot.10613</pub-id><pub-id pub-id-type="pmid">15048827</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Jacobson, M. P. et al. A hierarchical approach to all-atom protein loop prediction. <italic>Proteins</italic><bold>55</bold>, 351&#x02013;367 (2004).<pub-id pub-id-type="pmid">15048827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>MP</given-names></name><name><surname>Friesner</surname><given-names>RA</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Honig</surname><given-names>B</given-names></name></person-group><article-title>On the role of the crystal environment in determining protein side-chain conformations</article-title><source>J. Mol. Biol.</source><year>2002</year><volume>320</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(02)00470-9</pub-id><pub-id pub-id-type="pmid">12096912</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Jacobson, M. P., Friesner, R. A., Xiang, Z. &#x00026; Honig, B. On the role of the crystal environment in determining protein side-chain conformations. <italic>J. Mol. Biol.</italic><bold>320</bold>, 597&#x02013;608 (2002).<pub-id pub-id-type="pmid">12096912</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>